[
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ï¼Œé€™å¯èƒ½å°æ–¼æƒ³è¦å¢å¼·å…ç–«ç³»çµ±æˆ–æ”¹å–„æ•´é«”å¥åº·çš„äººä¾†èªªï¼Œå…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½å°é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ï¼Œè®“æ¶ˆè²»è€…èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·å„ªå‹¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§ï¼ˆglucoraphaninï¼‰åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥ï¼ˆVFDï¼‰å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªæ˜¯å¦æœ‰æ­£é¢å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡ç‚º4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†å…¶è‘¡è„ç³–æ‹‰æ³•å¯§ã€ç¸½ç•°ç¡«æ°°é…¸é¹½ï¼ˆITCsï¼‰å’ŒèŠ±é’ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å…¶æ°´åˆ†ä¿æŒèƒ½åŠ›ã€æ²¹è„‚ä¿æŒèƒ½åŠ›å’Œè†¨è„¹èƒ½åŠ›ç­‰å“è³ªæŒ‡æ¨™ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æé«˜äº†316.30%ï¼Œä¸¦ä¼´éš¨è‘—ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å¢åŠ ã€‚é€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦é¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ï¼Œé€™å¯èƒ½å°æ–¼æƒ³è¦å¢å¼·å…ç–«ç³»çµ±æˆ–æ”¹å–„æ•´é«”å¥åº·çš„äººä¾†èªªï¼Œå…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½å°é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ï¼Œè®“æ¶ˆè²»è€…èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·å„ªå‹¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§ï¼ˆglucoraphaninï¼‰åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥ï¼ˆVFDï¼‰å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªæ˜¯å¦æœ‰æ­£é¢å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶å°è±¡ç‚º4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†å…¶è‘¡è„ç³–æ‹‰æ³•å¯§ã€ç¸½ç•°ç¡«æ°°é…¸é¹½ï¼ˆITCsï¼‰å’ŒèŠ±é’ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å…¶æ°´åˆ†ä¿æŒèƒ½åŠ›ã€æ²¹è„‚ä¿æŒèƒ½åŠ›å’Œè†¨è„¹èƒ½åŠ›ç­‰å“è³ªæŒ‡æ¨™ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–æ‹‰æ³•å¯§å«é‡æé«˜äº†316.30%ï¼Œä¸¦ä¼´éš¨è‘—ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å¢åŠ ã€‚é€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦é¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ æƒ³çŸ¥é“é’èŠ±æ¤°èœæ€éº¼è®Šå¾—æ›´å¥åº·å—ï¼Ÿé€™è£¡æœ‰å€‹æœ‰è¶£çš„ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼\n\nç ”ç©¶äººå“¡æœ€è¿‘æ¢ç´¢äº†å¦‚ä½•é€éä¸€äº›ç‰¹åˆ¥çš„è™•ç†æ–¹æ³•ï¼Œä¾†æé«˜é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯å°æˆ‘å€‘å¥åº·æœ‰ç›Šçš„è˜¿è””ç¡«ç´ ã€‚é€™ç¨®æˆåˆ†å¯èƒ½å¹«åŠ©æˆ‘å€‘å¢å¼·å…ç–«ç³»çµ±ï¼Œæ¸›å°‘æŸäº›ç–¾ç—…çš„é¢¨éšªï¼\n\nä»–å€‘ä½¿ç”¨äº†ç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿäº†é€™å°é’èŠ±æ¤°èœèŠ½ä¸­ä¸€ç¨®å«è‘¡è„ç³–æ‹‰æ³•å¯§çš„æˆåˆ†çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œé€™ç¨®è™•ç†ä½¿å¾—è‘¡è„ç³–æ‹‰æ³•å¯§çš„å«é‡æé«˜äº†316.30%ï¼è€Œä¸”ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨ä¿æŒç‡Ÿé¤Šå’ŒæŠ—èŒæ´»æ€§æ–¹é¢ä¹Ÿè¡¨ç¾å¾—ç›¸ç•¶ä¸éŒ¯ã€‚\n\nâœ¨ é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è”—ç³–è™•ç†èƒ½é¡¯è‘—æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥æœ‰åŠ©æ–¼ä¿æŒè˜¿è””ç¡«ç´ å’ŒæŠ—èŒæ´»æ€§ã€‚\n3. é€™äº›ç™¼ç¾å¯èƒ½å°é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰å¹«åŠ©ï¼Œè®“æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·å„ªå‹¢ï¼\n\nä¸‹æ¬¡åƒé’èŠ±æ¤°èœæ™‚ï¼Œä¸å¦¨æƒ³æƒ³é€™äº›å°ç§˜å¯†å“¦ï¼",
    "image_prompt": "Create a flat design infographic explaining the experimental method and main results of a study on broccoli sprouts. Include simplified illustrations of broccoli or symbols representing sulforaphane, a simplified representation of the experimental subjects (like people or cells), arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as the increase in a specific protective effect or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…å¯èƒ½æœ‰å¹«åŠ©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»æ–¹å¼çš„è®ŠåŒ–ï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è®Šå¾—è¶Šä¾†è¶Šé‡è¦ï¼Œå› æ­¤é€™äº›ç™¼ç¾å¯èƒ½å°æ”¹å–„äººé¡å¥åº·æœ‰æ½›åœ¨çš„è²¢ç»ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ä½œç”¨ä¸Šï¼Œé€™å°æ–¼ç†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„æ½›åœ¨é†«ç™‚æ‡‰ç”¨éå¸¸é‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±çš„å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘èƒå–ä¾†ç²å¾—çš„ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä¾†æ¸¬é‡ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸Šçš„æ½›åŠ›ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœï¼Œä½†é¡¯ç¤ºå‡ºé€™äº›ç‰©è³ªå¯èƒ½å°å‘¼å¸ç³»çµ±å¥åº·æœ‰ç›Šã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç‚ç—‡ç›¸é—œçš„ç–¾ç—…å¯èƒ½æœ‰å¹«åŠ©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»æ–¹å¼çš„è®ŠåŒ–ï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è®Šå¾—è¶Šä¾†è¶Šé‡è¦ï¼Œå› æ­¤é€™äº›ç™¼ç¾å¯èƒ½å°æ”¹å–„äººé¡å¥åº·æœ‰æ½›åœ¨çš„è²¢ç»ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ä½œç”¨ä¸Šï¼Œé€™å°æ–¼ç†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„æ½›åœ¨é†«ç™‚æ‡‰ç”¨éå¸¸é‡è¦ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±çš„å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘èƒå–ä¾†ç²å¾—çš„ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä¾†æ¸¬é‡ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸Šçš„æ½›åŠ›ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœï¼Œä½†é¡¯ç¤ºå‡ºé€™äº›ç‰©è³ªå¯èƒ½å°å‘¼å¸ç³»çµ±å¥åº·æœ‰ç›Šã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿå…¶å¯¦è˜¿è””ä¸åªæ˜¯ç¾å‘³çš„é£Ÿæï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œæ¢è¨äº†è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°æˆ‘å€‘å‘¼å¸ç³»çµ±çš„å½±éŸ¿ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯é€™äº›å¤©ç„¶æˆåˆ†å¦‚ä½•ä¿è­·æˆ‘å€‘çš„å‘¼å¸é“ç´°èƒï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ–¹é¢ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†äººé¡çš„æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä¾†é€²è¡Œå¯¦é©—ï¼Œæ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘å°ç´°èƒçš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ä¸€ç¨®åç‚ºIL-6çš„ç™¼ç‚æŒ‡æ¨™ï¼Œä¸¦æå‡ç´°èƒå…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚é€™æ„å‘³è‘—é€™äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„å‘¼å¸å¥åº·æœ‰ç›Šï¼\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç™¼ç‚ã€‚  \n2. å®ƒå€‘èƒ½æå‡ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚  \n3. é€™äº›ç™¼ç¾éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªï¼Œä½†åˆæ­¥çµæœä»¤äººæœŸå¾…ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the effects of sulforaphane and black radish juice on bronchial epithelial cells. Include simplified icons representing sulforaphane and black radish, a simplified illustration of human bronchial cells, arrows or flow lines showing the experimental steps, and a section highlighting the main results, such as reduced inflammation and increased antioxidant activity.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±çš„åŒ–ç™‚é›–ç„¶æ˜¯ç›®å‰çš„ä¸»è¦æ²»ç™‚æ‰‹æ®µï¼Œä½†å…¶æ•ˆæœå’Œå‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°å‹çš„å¤©ç„¶ç”¢å“ï¼Œåƒæ˜¯é€™æ¬¡ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©ï¼Œå¯èƒ½æœƒç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœå…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£ä»¥æ²»ç™‚çš„ä¹³ç™Œäºå‹ï¼Œä¸»è¦ä¾è³´åŒ–ç™‚ä¾†æ§åˆ¶ç—…æƒ…ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€šéåˆæˆæ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¾†æé«˜æŠ—ç™Œæ•ˆæœï¼Œä¸¦è©•ä¼°é€™äº›æ–°åŒ–åˆç‰©åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–æ–¹é¢çš„æ½›åŠ›ï¼Œé€²è€Œå°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™Œæ•ˆæœé€²è¡Œè©•ä¼°ã€‚å¯¦é©—ä¸»è¦ä½¿ç”¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ï¼Œé€šéæ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ç™Œç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ä¾†è©•ä¼°å…¶æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ•ˆæœä¸Šè¡¨ç¾å‡ºæœ€é«˜çš„æ´»æ€§ï¼Œèƒ½é¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–å’Œå…¶ä»–æƒ¡æ€§è¡Œç‚ºï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚åœ¨é«”å…§å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aé€šéä¸‹èª¿æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ï¼ŒæŠ‘åˆ¶ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±çš„åŒ–ç™‚é›–ç„¶æ˜¯ç›®å‰çš„ä¸»è¦æ²»ç™‚æ‰‹æ®µï¼Œä½†å…¶æ•ˆæœå’Œå‰¯ä½œç”¨å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ã€‚å› æ­¤ï¼Œé–‹ç™¼æ–°å‹çš„å¤©ç„¶ç”¢å“ï¼Œåƒæ˜¯é€™æ¬¡ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é†‡çš„åˆæˆæ··åˆç‰©ï¼Œå¯èƒ½æœƒç‚ºæ‚£è€…æä¾›æ›´æœ‰æ•ˆä¸”å‰¯ä½œç”¨è¼ƒå°çš„æ²»ç™‚é¸æ“‡ï¼Œé€™å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªå’Œæ²»ç™‚æ•ˆæœå…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ã€‚ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£ä»¥æ²»ç™‚çš„ä¹³ç™Œäºå‹ï¼Œä¸»è¦ä¾è³´åŒ–ç™‚ä¾†æ§åˆ¶ç—…æƒ…ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€šéåˆæˆæ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¾†æé«˜æŠ—ç™Œæ•ˆæœï¼Œä¸¦è©•ä¼°é€™äº›æ–°åŒ–åˆç‰©åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–æ–¹é¢çš„æ½›åŠ›ï¼Œé€²è€Œå°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™Œæ•ˆæœé€²è¡Œè©•ä¼°ã€‚å¯¦é©—ä¸»è¦ä½¿ç”¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ï¼Œé€šéæ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ç™Œç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ä¾†è©•ä¼°å…¶æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä½¿ç”¨MDA-MB-231è…«ç˜¤æ¨¡å‹ä¾†è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦æª¢æŸ¥å…¶å°æ­£å¸¸å™¨å®˜çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ•ˆæœä¸Šè¡¨ç¾å‡ºæœ€é«˜çš„æ´»æ€§ï¼Œèƒ½é¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–å’Œå…¶ä»–æƒ¡æ€§è¡Œç‚ºï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚åœ¨é«”å…§å¯¦é©—ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªé¡¯ç¤ºå‡ºæ˜é¡¯çš„æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aé€šéä¸‹èª¿æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ï¼ŒæŠ‘åˆ¶ç›¸é—œåŸºå› çš„è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚å€™é¸è—¥ç‰©çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿè£¡å…¶å¯¦è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼æœ€è¿‘æœ‰ä¸€é …é‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰çš„ç ”ç©¶ï¼Œè®“æˆ‘å€‘çœ‹åˆ°å¤©ç„¶æˆåˆ†çš„å¸Œæœ›ï¼é€™ç¨®ç™Œç—‡ç‰¹åˆ¥é›£æ²»ç™‚ï¼Œå‚³çµ±åŒ–ç™‚å¸¸å¸¸è®“æ‚£è€…æ„Ÿåˆ°å›°æ“¾ï¼Œå› æ­¤ç§‘å­¸å®¶å€‘é–‹å§‹æ¢ç´¢æ–°çš„æ²»ç™‚æ–¹æ³•ã€‚  \n  \né€™é …ç ”ç©¶çš„é‡é»æ˜¯é–‹ç™¼ä¸€ç¨®æ–°çš„æœ¨è˜­é†‡-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç›®çš„æ˜¯æé«˜æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…åˆæˆäº†15ç¨®ä¸åŒçš„æ··åˆç‰©ï¼Œä¸¦æ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ï¼Œçœ‹çœ‹èƒ½å¦æŠ‘åˆ¶ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚  \n  \nçµæœé¡¯ç¤ºï¼ŒåŒ–åˆç‰©17aè¡¨ç¾æœ€ä½³ï¼Œèƒ½é¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å¢æ®–ï¼Œç”šè‡³ä¿ƒé€²ç™Œç´°èƒçš„å‡‹äº¡ã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œé€™å€‹åŒ–åˆç‰©ä¹Ÿæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”å°æ­£å¸¸å™¨å®˜æ²’æœ‰æ˜é¡¯æ¯’æ€§ã€‚é€™äº›ç™¼ç¾è®“äººæœŸå¾…ï¼Œæœªä¾†æˆ–è¨±èƒ½ç‚ºæ‚£è€…å¸¶ä¾†æ–°çš„æ²»ç™‚é¸æ“‡ï¼  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. ç ”ç©¶é‡å°é›£æ²»çš„ä¸‰é™°æ€§ä¹³ç™Œï¼Œå°‹æ‰¾æ–°å‹æŠ—ç™Œè—¥ç‰©ã€‚  \n2. åŒ–åˆç‰©17aé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—ç™Œæ•ˆæœï¼Œä¸”ç„¡æ˜é¡¯æ¯’æ€§ã€‚  \n3. æœªä¾†æœ‰æœ›é€²ä¸€æ­¥è‡¨åºŠç ”ç©¶ï¼Œç‚ºæ‚£è€…å¸¶ä¾†æ›´å¤šå¸Œæœ›ï¼",
    "image_prompt": "Create a flat design infographic illustrating the research on a new anticancer compound derived from natural ingredients. Include symbols for broccoli and sulforaphane, simplified representations of experimental subjects like cells and animals, and arrows or flow lines showing the experimental process. Highlight a section labeled 'Key Findings' showcasing the protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢ç™¼ç‚å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ²»ç™‚ç­–ç•¥ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†å¯èƒ½æœƒæœ‰æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å…ç–«ç³»çµ±çš„åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…æ™‚ï¼Œé€™å°æ–¼æ‚£è€…çš„å¥åº·ç®¡ç†å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨ä¿ƒé€²æ¨¹çªç´°èƒè€å—æ€§æ–¹é¢çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥ä¾¿èƒ½å¤ æ›´æœ‰æ•ˆåœ°æ‡‰ç”¨æ–¼è‡¨åºŠã€‚ç ”ç©¶ä¸­ï¼Œè˜¿è””ç¡«ç´ è¢«èˆ‡ç”˜éœ²ç³–ï¼ˆSFNManï¼‰æˆ–å²©è—»ç³–ï¼ˆSFNFucï¼‰çµåˆï¼Œç›®çš„æ˜¯åœ¨ç™¼ç‚ç‹€æ…‹ä¸‹èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼ˆmoDCsï¼‰ç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œä¸¦æ¢è¨NFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç™¼ç‚ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€SFNManæˆ–SFNFucé€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›æ¨¹çªç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­åˆ†æ³Œã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„æƒ…æ³ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè™•ç†å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•ä¿ƒé€²è€å—æ€§è¡¨å‹çš„å½¢æˆã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¸”ä¸Šèª¿äº†SOCS1å’ŒIDOçš„è½‰éŒ„æœ¬ï¼ŒåŒæ™‚ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒçš„æ“´å¢ï¼Œæ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚æ­¤å¤–ï¼ŒåŠŸèƒ½æ€§æ¸¬è©¦å’Œå…±ç„¦é¡¯å¾®é¡è§€å¯Ÿé¡¯ç¤ºï¼Œåªæœ‰SFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒNFATc1åœ¨SFNManèª˜å°çš„å…ç–«è€å—ä¸­æ‰®æ¼”äº†é‡è¦çš„è§’è‰²ï¼Œä¸¦ç‚ºé‡å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶æ¡†æ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢ç™¼ç‚å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ²»ç™‚ç­–ç•¥ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†å¯èƒ½æœƒæœ‰æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å…ç–«ç³»çµ±çš„åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…æ™‚ï¼Œé€™å°æ–¼æ‚£è€…çš„å¥åº·ç®¡ç†å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨ä¿ƒé€²æ¨¹çªç´°èƒè€å—æ€§æ–¹é¢çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä»¥ä¾¿èƒ½å¤ æ›´æœ‰æ•ˆåœ°æ‡‰ç”¨æ–¼è‡¨åºŠã€‚ç ”ç©¶ä¸­ï¼Œè˜¿è””ç¡«ç´ è¢«èˆ‡ç”˜éœ²ç³–ï¼ˆSFNManï¼‰æˆ–å²©è—»ç³–ï¼ˆSFNFucï¼‰çµåˆï¼Œç›®çš„æ˜¯åœ¨ç™¼ç‚ç‹€æ…‹ä¸‹èª˜å°äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼ˆmoDCsï¼‰ç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œä¸¦æ¢è¨NFATc1åœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç™¼ç‚ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€SFNManæˆ–SFNFucé€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›æ¨¹çªç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­åˆ†æ³Œã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1ä¿¡è™Ÿå‚³å°çš„æƒ…æ³ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨äº†è§£ä¸åŒè™•ç†å°æ¨¹çªç´°èƒåŠŸèƒ½çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•ä¿ƒé€²è€å—æ€§è¡¨å‹çš„å½¢æˆã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¸”ä¸Šèª¿äº†SOCS1å’ŒIDOçš„è½‰éŒ„æœ¬ï¼ŒåŒæ™‚ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒçš„æ“´å¢ï¼Œæ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚æ­¤å¤–ï¼ŒåŠŸèƒ½æ€§æ¸¬è©¦å’Œå…±ç„¦é¡¯å¾®é¡è§€å¯Ÿé¡¯ç¤ºï¼Œåªæœ‰SFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒNFATc1åœ¨SFNManèª˜å°çš„å…ç–«è€å—ä¸­æ‰®æ¼”äº†é‡è¦çš„è§’è‰²ï¼Œä¸¦ç‚ºé‡å°ç™¼ç‚å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶æ¡†æ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å…ç–«ç³»çµ±æœ‰æ™‚å€™æœƒå‡ºç¾å°å•é¡Œï¼Œåƒæ˜¯éåº¦åæ‡‰ï¼Œå°è‡´ç™¼ç‚æˆ–è‡ªé«”å…ç–«ç–¾ç—…ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½æˆç‚ºæ”¹å–„é€™äº›å•é¡Œçš„æ–°å¸Œæœ›ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¨¹çªç´°èƒï¼ˆæˆ‘å€‘å…ç–«ç³»çµ±ä¸­çš„å°å¹«æ‰‹ï¼‰è®Šå¾—æ›´è€å—ï¼Œæ¸›å°‘ç™¼ç‚ã€‚ç ”ç©¶è€…å€‘å°‡è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–æˆåˆ†çµåˆï¼Œä¸¦è§€å¯Ÿé€™äº›æ¨¹çªç´°èƒåœ¨ç™¼ç‚ç’°å¢ƒä¸­çš„åæ‡‰ã€‚\n\nä»–å€‘ç™¼ç¾ï¼Œç•¶æ¨¹çªç´°èƒæ¥è§¸åˆ°è˜¿è””ç¡«ç´ æ™‚ï¼Œå®ƒå€‘èƒ½å¤ è¡¨ç¾å‡ºè€å—æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå€‘ä¸æœƒéåº¦åæ‡‰ï¼Œå¾è€Œæ¸›å°‘ä¸å¿…è¦çš„ç™¼ç‚ã€‚è€Œä¸”ï¼Œé€™å€‹éç¨‹ä¸­æœ‰ä¸€å€‹ç‰¹æ®Šçš„è›‹ç™½è³ªå«åšNFATc1æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©å…ç–«ç³»çµ±æ›´å¥½åœ°æ§åˆ¶ç™¼ç‚ã€‚\n2. æ¨¹çªç´°èƒçš„è€å—æ€§å°æ–¼é é˜²è‡ªé«”å…ç–«ç–¾ç—…éå¸¸é‡è¦ã€‚\n3. NFATc1åœ¨é€™å€‹éç¨‹ä¸­èµ·è‘—é—œéµä½œç”¨ï¼Œæœªä¾†æˆ–è¨±èƒ½æˆç‚ºæ²»ç™‚çš„ç›®æ¨™ï¼",
    "image_prompt": "Create a flat design infographic with a light background depicting the experiment involving sulforaphane (SFN). Include simple illustrations of broccoli or sulforaphane, simplified representations of human or animal cells, and arrows indicating the experimental steps. Include a section labeled 'Main Results' highlighting protective effects and changes observed, such as increased tolerance in dendritic cells.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·çš„ä¿è­·ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿå—æçš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒé€ æˆç”Ÿå‘½å¨è„…ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…æ‰€é€ æˆçš„å‚·å®³ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„å•é¡Œï¼Œé€™äº›éƒ½æ˜¯TTSç™¼ç—…æ©Ÿåˆ¶ä¸­çš„é‡è¦å› ç´ ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å¿ƒè‡Ÿå¥åº·ï¼Œä¸¦é™ä½TTSçš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ¸›è¼•ç”±ç•°ä¸™è…ä¸Šè…ºç´ å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œä¸¦ä¸”äº†è§£å…¶åœ¨æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶ä¸­æåˆ°ï¼Œé›–ç„¶TTSçš„ç™¼ç—…æ©Ÿåˆ¶èˆ‡æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡æœ‰é—œï¼Œä½†ç›®å‰å°šç„¡é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†é€²è¡Œæ¸¬è©¦ã€‚é€™äº›æ¨¡å‹å¹«åŠ©ç ”ç©¶è€…è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½çš„æ¢å¾©æƒ…æ³ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…èƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿå¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’ŒæŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨èˆ‡Fer-1ï¼ˆä¸€ç¨®éµæ­»äº¡æŠ‘åˆ¶åŠ‘ï¼‰ç›¸ä¼¼ï¼Œä½†å®ƒç¨ç‰¹åœ°æ¿€æ´»äº†Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶Nrf2æœƒæ¶ˆé™¤è˜¿è””ç¡«ç´ çš„ç›Šè™•ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚åŠ‘ï¼Œå°æ–¼æ”¹å–„Takotsuboç—‡å€™ç¾¤çš„çµæœå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·çš„ä¿è­·ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿå—æçš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒé€ æˆç”Ÿå‘½å¨è„…ã€‚é€™é …ç ”ç©¶æ¢è¨äº†å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•é€™ç¨®ç–¾ç—…æ‰€é€ æˆçš„å‚·å®³ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„å•é¡Œï¼Œé€™äº›éƒ½æ˜¯TTSç™¼ç—…æ©Ÿåˆ¶ä¸­çš„é‡è¦å› ç´ ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å¿ƒè‡Ÿå¥åº·ï¼Œä¸¦é™ä½TTSçš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ¸›è¼•ç”±ç•°ä¸™è…ä¸Šè…ºç´ å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œä¸¦ä¸”äº†è§£å…¶åœ¨æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶ä¸­æåˆ°ï¼Œé›–ç„¶TTSçš„ç™¼ç—…æ©Ÿåˆ¶èˆ‡æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡æœ‰é—œï¼Œä½†ç›®å‰å°šç„¡é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†é€²è¡Œæ¸¬è©¦ã€‚é€™äº›æ¨¡å‹å¹«åŠ©ç ”ç©¶è€…è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½çš„æ¢å¾©æƒ…æ³ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…èƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿå¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’ŒæŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨èˆ‡Fer-1ï¼ˆä¸€ç¨®éµæ­»äº¡æŠ‘åˆ¶åŠ‘ï¼‰ç›¸ä¼¼ï¼Œä½†å®ƒç¨ç‰¹åœ°æ¿€æ´»äº†Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒæŠ‘åˆ¶Nrf2æœƒæ¶ˆé™¤è˜¿è””ç¡«ç´ çš„ç›Šè™•ï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚åŠ‘ï¼Œå°æ–¼æ”¹å–„Takotsuboç—‡å€™ç¾¤çš„çµæœå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿä¹Ÿæœƒå—åˆ°å£“åŠ›çš„å½±éŸ¿ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œçœ‹çœ‹å®ƒèƒ½å¦å¹«åŠ©ä¿è­·æˆ‘å€‘çš„å¿ƒè‡Ÿï¼Œç‰¹åˆ¥æ˜¯å°æŠ—ä¸€ç¨®å«åšTakotsuboç—‡å€™ç¾¤çš„å¿ƒè‡Ÿç–¾ç—…ã€‚é€™ç¨®ç—…éå»è¢«èªç‚ºä¸å¤ªåš´é‡ï¼Œä½†å…¶å¯¦å¯èƒ½æœƒå°ç”Ÿå‘½é€ æˆå¨è„…ã€‚ ç ”ç©¶è€…å€‘åˆ©ç”¨è€é¼ å’Œå¿ƒè‡Ÿç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›è¼•å¿ƒè‡Ÿæå‚·ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹èˆ‡åŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚æœ€æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ–¹å¼å’Œä¸€ç¨®å·²çŸ¥çš„éµæ­»äº¡æŠ‘åˆ¶åŠ‘ç›¸ä¼¼ï¼Œä½†å®ƒé‚„èƒ½æ¿€æ´»æˆ‘å€‘èº«é«”çš„å¤©ç„¶é˜²ç¦¦æ©Ÿåˆ¶ï¼é€™é …ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œæˆ–è¨±æœªä¾†èƒ½æˆç‚ºå¿ƒè‡Ÿå¥åº·çš„æ–°é¸æ“‡ã€‚ ä¾†çœ‹çœ‹é€™è£¡çš„é‡é»ï¼š\n- è˜¿è””ç¡«ç´ å¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰ç›Šã€‚\n- å®ƒèƒ½æ”¹å–„å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½ã€‚\n- æ¿€æ´»èº«é«”çš„å¤©ç„¶é˜²ç¦¦æ©Ÿåˆ¶ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on sulforaphane's effects on heart health. Use flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or heart cells, arrows or flow lines to show experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—æŸäº›ç–¾ç—…ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘éœ€è¦æ›´æœ‰æ•ˆçš„æ–¹æ³•ä¾†æå–å’Œåˆ©ç”¨é€™ç¨®åŒ–åˆç‰©ã€‚é€éäº†è§£å¾®ç”Ÿç‰©å¦‚ä½•è½‰æ›è˜¿è””ç¡«ç´ ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´å¥½çš„ä¿å¥é£Ÿå“æˆ–è—¥ç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œç–¾ç—…é é˜²ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ï¼Œä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†å¢å¼·è½‰æ›ç‡ï¼Œå¾è€Œä½¿è˜¿è””ç¡«ç´ çš„å¥åº·æ•ˆç›Šèƒ½å¤ æ›´å¥½åœ°ç™¼æ®ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è½‰æ›èƒ½åŠ›ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æå…¶ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸çš„ä»£è¬è®ŠåŒ–ã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºå¾®ç”Ÿç‰©å¦‚ä½•æœ‰æ•ˆåœ°å°‡è‘¡è„ç³–è‹·é…¸è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶æé«˜è‘¡è„ç³–æ›¿ä»£æ¯”ç‡æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒé¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡æœƒä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªåœ¨ä»£è¬ä¸Šæœ‰æ˜é¡¯çš„èª¿æ•´ï¼Œä¸¦ä¸”èƒ½å¤ æ›´æœ‰æ•ˆåœ°é€²è¡Œè˜¿è””ç¡«ç´ çš„è½‰æ›ã€‚é€™äº›çµæœæœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›äº†åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—æŸäº›ç–¾ç—…ã€‚ç„¶è€Œï¼Œè˜¿è””ç¡«ç´ çš„è½‰æ›ç‡è¼ƒä½ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘éœ€è¦æ›´æœ‰æ•ˆçš„æ–¹æ³•ä¾†æå–å’Œåˆ©ç”¨é€™ç¨®åŒ–åˆç‰©ã€‚é€éäº†è§£å¾®ç”Ÿç‰©å¦‚ä½•è½‰æ›è˜¿è””ç¡«ç´ ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´å¥½çš„ä¿å¥é£Ÿå“æˆ–è—¥ç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œç–¾ç—…é é˜²ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ï¼Œä»¥åŠå¦‚ä½•é€éå¯¦é©—æŠ€è¡“ä¾†å¢å¼·è½‰æ›ç‡ï¼Œå¾è€Œä½¿è˜¿è””ç¡«ç´ çš„å¥åº·æ•ˆç›Šèƒ½å¤ æ›´å¥½åœ°ç™¼æ®ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è½‰æ›èƒ½åŠ›ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬åˆ†æå…¶ä»£è¬é€”å¾‘ï¼Œç‰¹åˆ¥æ˜¯ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸çš„ä»£è¬è®ŠåŒ–ã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºå¾®ç”Ÿç‰©å¦‚ä½•æœ‰æ•ˆåœ°å°‡è‘¡è„ç³–è‹·é…¸è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„éç¨‹ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶æé«˜è‘¡è„ç³–æ›¿ä»£æ¯”ç‡æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒé¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡æœƒä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªåœ¨ä»£è¬ä¸Šæœ‰æ˜é¡¯çš„èª¿æ•´ï¼Œä¸¦ä¸”èƒ½å¤ æ›´æœ‰æ•ˆåœ°é€²è¡Œè˜¿è””ç¡«ç´ çš„è½‰æ›ã€‚é€™äº›çµæœæœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›äº†åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼ä½†é€™å€‹å¤©ç„¶åŒ–åˆç‰©çš„è½‰æ›ç‡ä¸é«˜ï¼Œè®“æˆ‘å€‘ä¾†çœ‹çœ‹æœ€æ–°çš„ç ”ç©¶æ˜¯æ€éº¼è§£æ±ºé€™å€‹å•é¡Œçš„ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•è®“ä¹³é…¸èŒï¼ˆå°±æ˜¯é‚£ç¨®å°è…¸é“å¥åº·æœ‰ç›Šçš„å¥½èŒï¼‰æ›´æœ‰æ•ˆåœ°æŠŠé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®ç‰©è³ªè½‰æ›æˆè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…å€‘ä¸åƒ…é—œå¿ƒè½‰æ›çš„éç¨‹ï¼Œé‚„æƒ³çŸ¥é“æ€éº¼æå‡é€™å€‹è½‰æ›ç‡ï¼Œè®“è˜¿è””ç¡«ç´ çš„å¥åº·æ•ˆç›Šæ›´å¥½åœ°ç™¼æ®ã€‚\n\nä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®å«é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ï¼Œä¾†æ”¹é€²ä¹³é…¸èŒçš„è½‰æ›èƒ½åŠ›ã€‚é€éåˆ†æé€™äº›å¾®ç”Ÿç‰©çš„ä»£è¬è®ŠåŒ–ï¼Œç ”ç©¶è€…å€‘å¸Œæœ›æ‰¾å‡ºå¦‚ä½•è®“å®ƒå€‘æ›´æœ‰æ•ˆç‡åœ°é€²è¡Œé€™å€‹è½‰æ›ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç•¶æé«˜è‘¡è„ç³–çš„æ›¿ä»£æ¯”ç‡æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸çš„ä»£è¬å‰‡æœƒä¸Šå‡ï¼é€™æ„å‘³è‘—é€™äº›é€²åŒ–éçš„ä¹³é…¸èŒèƒ½æ›´å¥½åœ°å°‡é’èŠ±æ¤°èœä¸­çš„æˆåˆ†è½‰æ›æˆè˜¿è””ç¡«ç´ ï¼Œé€™å°æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©å’Œå¤©ç„¶ç‰©è³ªä¹‹é–“çš„é—œä¿‚æœ‰å¾ˆå¤§å¹«åŠ©ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¥åº·æœ‰æ½›åœ¨ç›Šè™•ã€‚\n2. ä¹³é…¸èŒçš„è½‰æ›èƒ½åŠ›å¯ä»¥é€éå¯¦é©—æŠ€è¡“æå‡ã€‚\n3. ç†è§£å¾®ç”Ÿç‰©çš„ä»£è¬éç¨‹æœ‰åŠ©æ–¼æœªä¾†é–‹ç™¼ä¿å¥é£Ÿå“ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main findings of a study on sulforaphane from broccoli. Include simple illustrations of broccoli and sulforaphane, as well as simplified representations of the experimental subjects like bacteria. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting key findings such as metabolic changes in bacteria.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°å¸¸è¦‹çš„çœŸèŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ™‚ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é¡¯è‘—é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å…·æœ‰ä¿è­·è…¸é“çš„æ•ˆæœï¼Œé€™å°æ–¼æ¸›å°‘ç”±DONå¼•èµ·çš„è…¸é“æå‚·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é™ä½å› é£Ÿç”¨å—æ±¡æŸ“é£Ÿç‰©è€Œå¼•ç™¼çš„å¥åº·å•é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç”±è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•é‹ä½œã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©æ´»æ€§ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°é£Ÿç‰©ä¸­æ¯’å’Œè…¸é“å¥åº·å•é¡Œæ™‚ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°å…¶ä¿è­·æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“æœ‰æ©Ÿé«”é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡å’Œæµå¼ç´°èƒè¡“ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡æº¶é…¶é«”åŠŸèƒ½æœ‰é—œï¼Œä¸¦ä¸”é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•è…¸é“æå‚·æ–¹é¢çš„æ½›åœ¨æ©Ÿåˆ¶æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦æŒ‡å‡ºäº†æœªä¾†é€²ä¸€æ­¥ç ”ç©¶çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°å¸¸è¦‹çš„çœŸèŒæ¯’ç´ è„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰æ™‚ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é¡¯è‘—é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å…·æœ‰ä¿è­·è…¸é“çš„æ•ˆæœï¼Œé€™å°æ–¼æ¸›å°‘ç”±DONå¼•èµ·çš„è…¸é“æå‚·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¢åŠ æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é™ä½å› é£Ÿç”¨å—æ±¡æŸ“é£Ÿç‰©è€Œå¼•ç™¼çš„å¥åº·å•é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç”±è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›èƒ½å¤ ç¢ºèªè˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•é‹ä½œã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©æ´»æ€§ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°é£Ÿç‰©ä¸­æ¯’å’Œè…¸é“å¥åº·å•é¡Œæ™‚ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆè„«æ°§é›ªè…çƒ¯é†‡å’Œè˜¿è””ç¡«ç´ ï¼Œä»¥è©•ä¼°å…¶ä¿è­·æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“æœ‰æ©Ÿé«”é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡å’Œæµå¼ç´°èƒè¡“ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†è„«æ°§é›ªè…çƒ¯é†‡å¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡æº¶é…¶é«”åŠŸèƒ½æœ‰é—œï¼Œä¸¦ä¸”é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•è…¸é“æå‚·æ–¹é¢çš„æ½›åœ¨æ©Ÿåˆ¶æä¾›äº†æ–°çš„è¦‹è§£ï¼Œä¸¦æŒ‡å‡ºäº†æœªä¾†é€²ä¸€æ­¥ç ”ç©¶çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“å¥åº·è·Ÿæˆ‘å€‘åƒçš„é£Ÿç‰©æ¯æ¯ç›¸é—œï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ä¸€ç¨®å«åšè„«æ°§é›ªè…çƒ¯é†‡ï¼ˆDONï¼‰çš„çœŸèŒæ¯’ç´ ï¼Œé€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­ç›¸ç•¶å¸¸è¦‹ï¼Œå°å¥åº·æœ‰æ½›åœ¨å¨è„…ã€‚  \n  \nç ”ç©¶è€…å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›å°‘ç”±é€™ç¨®æ¯’ç´ å¼•èµ·çš„è…¸é“æå‚·ã€‚ä»–å€‘ä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œå¯¦é©—ï¼Œç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•è…¸é“çš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ”¹å–„è…¸é“çš„çµæ§‹å’ŒåŠŸèƒ½ã€‚  \n  \né€™é …ç ”ç©¶çš„çµæœè®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éå¢åŠ æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘çš„è…¸é“æ›´å¥åº·ï¼  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“æå‚·ã€‚  \n2. å¯¦é©—é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“çµæ§‹å’Œæ°§åŒ–é‚„åŸå¹³è¡¡ã€‚  \n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¥åº·å¹²é æä¾›äº†æ–°çš„ç§‘å­¸ä¾æ“šã€‚",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane, a compound found in cruciferous vegetables like broccoli. The image should have a flat design style with a white or light background and soft colors. Include simple icons representing broccoli or sulforaphane, experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè¡°è€ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³å½±éŸ¿ã€‚é€éå¢å¼·ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œè˜¿è””ç¡«ç´ æˆ–è¨±èƒ½åœ¨ä¸€å®šç¨‹åº¦ä¸Šä¿è­·è‚ºéƒ¨ç´°èƒï¼Œæ¸›å°‘å› å¸ç…™å¼•èµ·çš„æå‚·ï¼Œé€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·è¨Šæ¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸ç…™æ‰€é‡‹æ”¾çš„ç…™éœ§æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä¸¦å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€SIRT1çš„è¡¨é”ä¾†æ¸›è¼•é€™äº›æå‚·ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¶‰åŠç´°èƒå±¤é¢çš„å¯¦é©—ï¼Œé‚„åŒ…æ‹¬å‹•ç‰©æ¨¡å‹çš„ç ”ç©¶ï¼Œç›®çš„æ˜¯å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œé€™äº›ç´°èƒè¢«è™•ç†äº†å¸ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€šéMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè¡°è€çš„æƒ…æ³ï¼Œä¸¦é€éqRT-PCRé‡æ¸¬èˆ‡è¡°è€ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†CSEä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†å°è‚ºéƒ¨çµ„ç¹”çš„å½±éŸ¿ï¼Œé€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›è¼•äº†å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è¡°è€åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™ç…™éœ§å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ç¾è±¡ï¼Œä¸¦é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶éµæ­»äº¡ï¼Œé™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè¡°è€å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè¡°è€ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³å½±éŸ¿ã€‚é€éå¢å¼·ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œè˜¿è””ç¡«ç´ æˆ–è¨±èƒ½åœ¨ä¸€å®šç¨‹åº¦ä¸Šä¿è­·è‚ºéƒ¨ç´°èƒï¼Œæ¸›å°‘å› å¸ç…™å¼•èµ·çš„æå‚·ï¼Œé€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·è¨Šæ¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸ç…™æ‰€é‡‹æ”¾çš„ç…™éœ§æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä¸¦å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€SIRT1çš„è¡¨é”ä¾†æ¸›è¼•é€™äº›æå‚·ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¶‰åŠç´°èƒå±¤é¢çš„å¯¦é©—ï¼Œé‚„åŒ…æ‹¬å‹•ç‰©æ¨¡å‹çš„ç ”ç©¶ï¼Œç›®çš„æ˜¯å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒï¼Œé€™äº›ç´°èƒè¢«è™•ç†äº†å¸ç…™ç…™éœ§æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦é€šéMTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè¡°è€çš„æƒ…æ³ï¼Œä¸¦é€éqRT-PCRé‡æ¸¬èˆ‡è¡°è€ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†CSEä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†å°è‚ºéƒ¨çµ„ç¹”çš„å½±éŸ¿ï¼Œé€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›è¼•äº†å¸ç…™ç…™éœ§æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è¡°è€åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™ç…™éœ§å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ç¾è±¡ï¼Œä¸¦é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶éµæ­»äº¡ï¼Œé™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè¡°è€å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ å¸ç…™å°æˆ‘å€‘çš„è‚ºéƒ¨æœ‰å¤šå¤§å‚·å®³ï¼Ÿé€™æ˜¯ä¸€å€‹å€¼å¾—é—œå¿ƒçš„å•é¡Œï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹ä¾†è‡ªè”¬èœçš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°æŠ—å¸ç…™é€ æˆçš„è‚ºéƒ¨æå‚·æœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†å¸ç…™ç…™éœ§å°æˆ‘å€‘å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ï¼Œä¸¦ä¸”çœ‹çœ‹è˜¿è””ç¡«ç´ å¦‚ä½•ç™¼æ®ä½œç”¨ã€‚ç ”ç©¶è€…å€‘ç”¨äººé¡ç´°èƒå’Œå°é¼ é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ¸›è¼•å¸ç…™å¼•èµ·çš„æå®³ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›å°‘ç´°èƒçš„æ­»äº¡å’Œè¡°è€ï¼Œé‚„èƒ½æ”¹å–„å°é¼ çš„è‚ºéƒ¨å¥åº·ï¼é€™æ„å‘³è‘—ï¼Œå°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œè˜¿è””ç¡«ç´ æˆ–è¨±èƒ½æä¾›ä¸€äº›ä¿è­·ã€‚\n\nâœ¨ é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³ã€‚  \n2. å®ƒèƒ½é™ä½ç´°èƒè¡°è€å’Œç›¸é—œçš„ç‚ç—‡åæ‡‰ã€‚  \n3. å°æ–¼å¸ç…™è€…ï¼Œå¢åŠ è˜¿è””ç¡«ç´ çš„æ”å–å¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—è€ƒæ…®çš„å¥åº·é¸æ“‡ï¼  \nè¨˜å¾—å¤šåƒå¥åº·è”¬èœï¼Œè®“æˆ‘å€‘çš„èº«é«”æ›´å¼·å£¯ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the protective effects of sulforaphane against smoking-induced lung damage. The image should include symbols representing broccoli or sulforaphane, simplified illustrations of human cells and mice as experimental subjects, arrows or flow lines indicating experimental steps, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šè€åŒ–æœƒå°è‡´çµæ§‹åŠŸèƒ½ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿åˆ°æˆ‘å€‘çš„å¥åº·å’Œç”Ÿæ´»å“è³ªã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå®ƒåœ¨æŠ—ç™¼ç‚æ–¹é¢æœ‰è‰¯å¥½çš„æ•ˆæœï¼Œä¸¦ä¸”åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­è¢«å»£æ³›æ‡‰ç”¨ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ¸›ç·©çš®è†šå…§éƒ¨è€åŒ–æœ‰å¹«åŠ©ï¼Œé€™å°æ–¼å¸Œæœ›ä¿æŒçš®è†šå¥åº·å’Œå¹´è¼•çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯å’Œå¯èƒ½çš„è§£æ±ºæ–¹æ¡ˆã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¹´é½¡å¢é•·æ‰€å¸¶ä¾†çš„çš®è†šè€åŒ–éç¨‹ä¸­ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œé€²è€Œæ”¹å–„äººå€‘çš„çš®è†šå¥åº·ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€å€‹18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿäº†å…©å€‹æœˆå¾Œçš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦ä¸”é€šéæ¿€æ´»apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºå°æŠ—å…§éƒ¨çš®è†šè€åŒ–çš„æ–°ç›®æ¨™ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„çš®è†šçµæ§‹å’Œå¢å¼·å…ç–«åæ‡‰æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šè€åŒ–æœƒå°è‡´çµæ§‹åŠŸèƒ½ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿åˆ°æˆ‘å€‘çš„å¥åº·å’Œç”Ÿæ´»å“è³ªã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå®ƒåœ¨æŠ—ç™¼ç‚æ–¹é¢æœ‰è‰¯å¥½çš„æ•ˆæœï¼Œä¸¦ä¸”åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­è¢«å»£æ³›æ‡‰ç”¨ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ¸›ç·©çš®è†šå…§éƒ¨è€åŒ–æœ‰å¹«åŠ©ï¼Œé€™å°æ–¼å¸Œæœ›ä¿æŒçš®è†šå¥åº·å’Œå¹´è¼•çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯å’Œå¯èƒ½çš„è§£æ±ºæ–¹æ¡ˆã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œç‰¹åˆ¥æ˜¯åœ¨å¹´é½¡å¢é•·æ‰€å¸¶ä¾†çš„çš®è†šè€åŒ–éç¨‹ä¸­ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œé€²è€Œæ”¹å–„äººå€‘çš„çš®è†šå¥åº·ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€å€‹18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿäº†å…©å€‹æœˆå¾Œçš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„çš®è†šçš„å½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œä¸¦ä¸”é€šéæ¿€æ´»apelinä¿¡è™Ÿé€šè·¯ä¾†é”æˆé€™äº›æ•ˆæœã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºå°æŠ—å…§éƒ¨çš®è†šè€åŒ–çš„æ–°ç›®æ¨™ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„çš®è†šçµæ§‹å’Œå¢å¼·å…ç–«åæ‡‰æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ æœ‰æ²’æœ‰æƒ³éï¼Œéš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šä¸å†é‚£éº¼å…‰æ»‘å’Œç·Šç·»ï¼Œé€™æ˜¯ç‚ºä»€éº¼å‘¢ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå°æŠ—çš®è†šè€åŒ–çš„æ½›åŠ›è®“äººè€³ç›®ä¸€æ–°ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„å¥åº·ï¼Œå°¤å…¶æ˜¯åœ¨æˆ‘å€‘å¹´ç´€å¢é•·å¾Œçš„è®ŠåŒ–ã€‚ ç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è€åŒ–å°é¼ æ¨¡å‹ï¼Œå°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿäº†å…©å€‹æœˆå¾Œçš„çš®è†šè®ŠåŒ–ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†çš®è†šçš„çµæ§‹ï¼Œé‚„å¢å¼·äº†å…ç–«åŠŸèƒ½ï¼Œé€™äº›æ•ˆæœæ˜¯é€éæ¿€æ´»ä¸€æ¢ç‰¹æ®Šçš„ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é›–ç„¶é€™äº›ç™¼ç¾ä»¤äººèˆˆå¥®ï¼Œä½†é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ©Ÿåˆ¶ã€‚ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›ç·©çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬çš®è†šè€åŒ–éç¨‹ã€‚\n3. è˜¿è””ç¡«ç´ æ”¹å–„çš®è†šçµæ§‹å’Œå¢å¼·å…ç–«åæ‡‰ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on a natural compound called sulforaphane. Include symbols representing broccoli or sulforaphane, simplified graphics of experimental subjects like mice, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects and changes observed in skin structure and immune function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼å°‹æ‰¾ä¿è­·è‚è‡Ÿå’Œæ”¹å–„å…ç–«ç³»çµ±çš„å¤©ç„¶æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é£²é£Ÿä¸­å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œä¸¦è€ƒæ…®å…¶åœ¨æ—¥å¸¸é£²é£Ÿä¸­çš„æ‡‰ç”¨ï¼Œä»¥ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™äº›éç¨‹ä¸­å¯èƒ½æ‰®æ¼”çš„è§’è‰²ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£å…¶æ½›åœ¨çš„ä¿è­·æ©Ÿåˆ¶ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šï¼ˆCyprinus carpioï¼‰ä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨å¯¦é©—ä¸­æš´éœ²æ–¼é€™äº›ç‰©è³ªä¸­æŒçºŒäº†8é€±ã€‚ç ”ç©¶è€…é€šéæ¸¬é‡è‚è‡Ÿçš„ç¸½è†½é¹½å’Œç¸½è†½å›ºé†‡æ°´å¹³ï¼Œä»¥åŠåŸºå› è¡¨é”çš„è®ŠåŒ–ï¼Œä¾†è©•ä¼°ä¸‰è‹¯éŒ«çš„æ¯’æ€§å½±éŸ¿åŠè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿçš„æ¯’æ€§åæ‡‰ï¼Œä¸¦ä¸”å½±éŸ¿äº†å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚è˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è†½é¹½çš„ç©ç´¯ï¼Œä¸¦æ¢å¾©æŸäº›åŸºå› çš„æ­£å¸¸è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶çš„ç·©è§£ä½œç”¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œå¢åŠ æœ‰ç›ŠèŒçš„æ¯”ä¾‹ï¼Œä¸¦æ¢å¾©è…¸é“çš„è½‰éŒ„çµ„å¤±èª¿ï¼Œé€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¯’æ€§ç·©è§£ç­–ç•¥ä¸­çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«åŠŸèƒ½æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½å¤±èª¿ï¼Œé€™å°æ–¼å°‹æ‰¾ä¿è­·è‚è‡Ÿå’Œæ”¹å–„å…ç–«ç³»çµ±çš„å¤©ç„¶æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿äººå€‘æ›´åŠ é‡è¦–é£²é£Ÿä¸­å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œä¸¦è€ƒæ…®å…¶åœ¨æ—¥å¸¸é£²é£Ÿä¸­çš„æ‡‰ç”¨ï¼Œä»¥ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸‰è‹¯éŒ«é€™ç¨®åŒ–å­¸ç‰©è³ªå°å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™äº›éç¨‹ä¸­å¯èƒ½æ‰®æ¼”çš„è§’è‰²ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£å…¶æ½›åœ¨çš„ä¿è­·æ©Ÿåˆ¶ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šï¼ˆCyprinus carpioï¼‰ä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ 10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨å¯¦é©—ä¸­æš´éœ²æ–¼é€™äº›ç‰©è³ªä¸­æŒçºŒäº†8é€±ã€‚ç ”ç©¶è€…é€šéæ¸¬é‡è‚è‡Ÿçš„ç¸½è†½é¹½å’Œç¸½è†½å›ºé†‡æ°´å¹³ï¼Œä»¥åŠåŸºå› è¡¨é”çš„è®ŠåŒ–ï¼Œä¾†è©•ä¼°ä¸‰è‹¯éŒ«çš„æ¯’æ€§å½±éŸ¿åŠè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿçš„æ¯’æ€§åæ‡‰ï¼Œä¸¦ä¸”å½±éŸ¿äº†å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚è˜¿è””ç¡«ç´ çš„è£œå……èƒ½å¤ æ¸›å°‘è†½é¹½çš„ç©ç´¯ï¼Œä¸¦æ¢å¾©æŸäº›åŸºå› çš„æ­£å¸¸è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶çš„ç·©è§£ä½œç”¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œå¢åŠ æœ‰ç›ŠèŒçš„æ¯”ä¾‹ï¼Œä¸¦æ¢å¾©è…¸é“çš„è½‰éŒ„çµ„å¤±èª¿ï¼Œé€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ¯’æ€§ç·©è§£ç­–ç•¥ä¸­çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å°èº«é«”æœ‰ä»€éº¼å¥½è™•å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘å°é€™å€‹å¤©ç„¶æˆåˆ†æœ‰äº†æ–°çš„èªè­˜ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›å°‘ä¸‰è‹¯éŒ«ï¼ˆé€™æ˜¯ä¸€ç¨®æœ‰å®³åŒ–å­¸ç‰©è³ªï¼‰å°è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å‚·å®³ã€‚ç§‘å­¸å®¶ç”¨é¯‰é­šä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é­šåˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒçš„è™•ç†ï¼ŒæŒçºŒè§€å¯Ÿäº†8é€±ã€‚\n\nçµæœç™¼ç¾ï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦æœƒå°è‚è‡Ÿé€ æˆæ¯’æ€§å½±éŸ¿ï¼Œä¸¦ä¸”æœƒå½±éŸ¿å…ç–«ç³»çµ±çš„åŠŸèƒ½ã€‚ä¸éï¼Œç•¶é­šçš„é£²é£Ÿä¸­åŠ å…¥è˜¿è””ç¡«ç´ å¾Œï¼Œè†½é¹½çš„ç©ç´¯æ¸›å°‘ï¼ŒæŸäº›åŸºå› çš„æ­£å¸¸è¡¨é”ä¹Ÿå¾—ä»¥æ¢å¾©ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å°æŠ—é€™äº›å‚·å®³çš„æ½›åŠ›ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œè®“æœ‰ç›Šçš„ç´°èŒå¢åŠ ã€‚\n\nâœ¨ ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1ï¸âƒ£ è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿå’Œå…ç–«ç³»çµ±ã€‚\n2ï¸âƒ£ å®ƒèƒ½æ¸›å°‘æœ‰å®³ç‰©è³ªå¼•èµ·çš„æ¯’æ€§åæ‡‰ã€‚\n3ï¸âƒ£ è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è…¸é“å¥åº·ï¼Œå¢å¼·æœ‰ç›ŠèŒçš„æ¯”ä¾‹ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°é£²é£Ÿä¸­å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©æ›´åŠ é‡è¦–ï¼Œæˆ–è¨±åœ¨æœªä¾†ï¼Œæˆ‘å€‘å¯ä»¥é€éé£²é£Ÿä¾†å¹«åŠ©æˆ‘å€‘çš„å¥åº·ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on the protective effects of sulforaphane from broccoli against toxicity from tributyltin. Include simplified icons of broccoli and fish as experimental subjects, arrows or flow lines to represent the experimental process, and a section labeled 'Main Results' highlighting the protective effects and changes observed in liver and gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„è®ŠåŒ–æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘è…¸é“ç‚ç—‡æœ‰å¹«åŠ©ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é é˜²ç›¸é—œç–¾ç—…çš„ç™¼ç”Ÿã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç‚ç—‡å’Œå±éšœåŠŸèƒ½å—æã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€šéå½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå…¶ä»£è¬ç‰©ä¾†æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—…ç†ç‹€æ³ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•ï¼Œä¹Ÿç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†åŸºç¤ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æå’Œä»£è¬çµ„å­¸çš„è©•ä¼°ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆåŠå…¶ä»£è¬éç¨‹ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„å°é¼ è…¸é“ç—…ç†ç‹€æ³ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬çµ„å­¸åˆ†æä¸­ç™¼ç¾ï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–ä¹Ÿå¾—åˆ°äº†æ”¹å–„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ï¼Œä¾†æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚ç—‡ï¼Œç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„è®ŠåŒ–æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘è…¸é“ç‚ç—‡æœ‰å¹«åŠ©ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©æ”¹å–„è…¸é“å¥åº·ï¼Œä¸¦é é˜²ç›¸é—œç–¾ç—…çš„ç™¼ç”Ÿã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç‚ç—‡å’Œå±éšœåŠŸèƒ½å—æã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•é€šéå½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå…¶ä»£è¬ç‰©ä¾†æ”¹å–„é€™ç¨®ç–¾ç—…çš„ç—…ç†ç‹€æ³ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç›Šè™•ï¼Œä¹Ÿç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†åŸºç¤ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æå’Œä»£è¬çµ„å­¸çš„è©•ä¼°ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆåŠå…¶ä»£è¬éç¨‹ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„å°é¼ è…¸é“ç—…ç†ç‹€æ³ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬çµ„å­¸åˆ†æä¸­ç™¼ç¾ï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–ä¹Ÿå¾—åˆ°äº†æ”¹å–„ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ï¼Œä¾†æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚ç—‡ï¼Œç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“è˜¿è””ä¸åƒ…åƒ…æ˜¯æ²™æ‹‰çš„é…è§’å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ä¸­çš„ä¸€ç¨®æˆåˆ†â€”â€”è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°è…¸é“å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯æ½°ç˜æ€§çµè…¸ç‚ï¼Œé€™æ˜¯ä¸€ç¨®æœƒå°è‡´è…¸é“ç™¼ç‚çš„æ…¢æ€§ç–¾ç—…ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“çš„å¾®ç”Ÿç‰©ç¾¤ï¼Œä¸¦æ”¹å–„é€™ç¨®ç–¾ç—…çš„æƒ…æ³ã€‚ç‚ºäº†é€²è¡Œå¯¦é©—ï¼Œä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®ç‰¹å®šçš„çµè…¸ç‚å°é¼ ï¼Œä¸¦çµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿè…¸é“çš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„å°é¼ çš„è…¸é“ç‹€æ³ï¼Œå¹«åŠ©æ¢å¾©è…¸é“çš„å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç‚ç—‡ï¼æ›´æœ‰è¶£çš„æ˜¯ï¼Œå®ƒé‚„èƒ½é‡æ–°å¹³è¡¡è…¸é“ä¸­çš„å¾®ç”Ÿç‰©ï¼Œé€™å°è…¸é“å¥åº·éå¸¸é‡è¦ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ã€‚\n2. å®ƒå°æ¸›å°‘è…¸é“ç‚ç—‡æœ‰æ½›åœ¨çš„ç›Šè™•ã€‚\n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on the effects of sulforaphane from radishes on intestinal health. Include simple illustrations of radishes and broccoli, simplified representations of mice as experimental subjects, and arrows or flow lines indicating the experimental steps. Add a section labeled 'Main Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŸäº›ç™Œç—‡æœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦ä¸”é€éç´ç±³è„‚è³ªé«”çš„å½¢å¼ï¼Œå¯ä»¥é€²ä¸€æ­¥å¢å¼·å…¶æ•ˆæœã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¯èƒ½æœƒåˆ©ç”¨é€™ç¨®æ–°å‹çš„è—¥ç‰©å‚³éç³»çµ±ä¾†æé«˜æ²»ç™‚æ•ˆæœï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ï¼Œè®“æ‚£è€…çš„ç”Ÿæ´»å“è³ªæ›´å¥½ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å°é¼ è‰¾çˆ¾å¸Œç™Œï¼ˆEhrlich Ascites Carcinoma, EACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç‰¹å®šç™Œç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥åŠä½¿ç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æé«˜å…¶æŠ—ç™Œæ•ˆæœã€‚é€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦çš„æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡ç‰ å€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªæ²»ç™‚çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€ä»¥åŠå¸¶æœ‰è‰¾çˆ¾å¸Œç™Œçš„çµ„åˆ¥ï¼Œé‚„æœ‰å…©çµ„æ˜¯åŒæ™‚çµ¦äºˆè˜¿è””ç¡«ç´ å’Œç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿè…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œç”Ÿç‰©æ¨™è¨˜çš„è®ŠåŒ–ï¼Œä»¥è©•ä¼°æ²»ç™‚æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç³»çµ±æ€§ç‚ç—‡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œä¸¦ä¸”èƒ½å¤ ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŸäº›ç™Œç—‡æœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦ä¸”é€éç´ç±³è„‚è³ªé«”çš„å½¢å¼ï¼Œå¯ä»¥é€²ä¸€æ­¥å¢å¼·å…¶æ•ˆæœã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„ç™Œç—‡æ²»ç™‚å¯èƒ½æœƒåˆ©ç”¨é€™ç¨®æ–°å‹çš„è—¥ç‰©å‚³éç³»çµ±ä¾†æé«˜æ²»ç™‚æ•ˆæœï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ï¼Œè®“æ‚£è€…çš„ç”Ÿæ´»å“è³ªæ›´å¥½ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å°é¼ è‰¾çˆ¾å¸Œç™Œï¼ˆEhrlich Ascites Carcinoma, EACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç‰¹å®šç™Œç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä»¥åŠä½¿ç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æé«˜å…¶æŠ—ç™Œæ•ˆæœã€‚é€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦çš„æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡ç‰ å€‘åˆ†æˆå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªæ²»ç™‚çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€ä»¥åŠå¸¶æœ‰è‰¾çˆ¾å¸Œç™Œçš„çµ„åˆ¥ï¼Œé‚„æœ‰å…©çµ„æ˜¯åŒæ™‚çµ¦äºˆè˜¿è””ç¡«ç´ å’Œç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿè…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œç”Ÿç‰©æ¨™è¨˜çš„è®ŠåŒ–ï¼Œä»¥è©•ä¼°æ²»ç™‚æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³å½¢å¼çš„è˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘æ°§åŒ–å£“åŠ›å’Œç³»çµ±æ€§ç‚ç—‡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œä¸¦ä¸”èƒ½å¤ ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿå…¶å¯¦æˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›æˆåˆ†å¯èƒ½å°æŠ—ç™Œæœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™å€‹æˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯é€éç´ç±³è„‚è³ªé«”çš„å½¢å¼ï¼Œå¯èƒ½å°æŸäº›ç™Œç—‡æœ‰æŠ‘åˆ¶ä½œç”¨ã€‚é€™è½èµ·ä¾†å¾ˆå²å®³å§ï¼Ÿ\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é‡å°å°é¼ çš„è‰¾çˆ¾å¸Œç™Œï¼ˆEACï¼‰é€²è¡Œæ¢è¨ï¼Œç ”ç©¶è€…æƒ³äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç™Œç—‡ä¸­çš„ä½œç”¨ï¼Œä»¥åŠç”¨ç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¢å¼·æŠ—ç™Œæ•ˆæœã€‚å¯¦é©—ä¸­ï¼Œ90éš»å°é¼ è¢«åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œæ¥å—ä¸åŒçš„è™•ç†ï¼ŒæŒçºŒè§€å¯Ÿ20å¤©ï¼Œçœ‹çœ‹è…«ç˜¤çš„è®ŠåŒ–å’Œå°é¼ çš„å­˜æ´»ç‡ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œç´ç±³è„‚è³ªé«”åŒ…è£¹çš„è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œä¿è­·è‚è‡Ÿæ–¹é¢ï¼Œæ•ˆæœæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´å¥½ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€™ç¨®æ–°å‹çš„è—¥ç‰©å‚³éç³»çµ±å¯èƒ½æœƒæˆç‚ºæœªä¾†ç™Œç—‡æ²»ç™‚çš„ä¸€å€‹é‡è¦å·¥å…·ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—æŸäº›ç™Œç—‡æœ‰å¹«åŠ©ã€‚\n2. ç´ç±³è„‚è³ªé«”èƒ½å¢å¼·è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ•ˆæœã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane (SFN). Include simplified illustrations of broccoli or sulforaphane, as well as simplified representations of experimental subjects like mice or cells. Use arrows or flow lines to show the steps of the experiment. Add a section labeled 'Main Results' that highlights the protective effects and changes observed in the study, using soft colors on a white or light background.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‰¾çˆ¾å¸Œç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·èˆ‡æ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²æˆ–æ²»ç™‚èƒƒç™Œçš„æ–¹æ³•ï¼Œå¹«åŠ©æ‚£è€…æ”¹å–„ç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œé‚„èƒ½å¹«åŠ©ç§‘å­¸å®¶å€‘æ›´æ·±å…¥åœ°ç†è§£èƒƒç™Œçš„ç™¼å±•éç¨‹ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—æ–¹æ³•ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œé€²ä¸€æ­¥çš„å¯¦é©—é©—è­‰äº†åƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œå¾è€Œæ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œä»ç„¶æ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·èˆ‡æ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²æˆ–æ²»ç™‚èƒƒç™Œçš„æ–¹æ³•ï¼Œå¹«åŠ©æ‚£è€…æ”¹å–„ç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œé‚„èƒ½å¹«åŠ©ç§‘å­¸å®¶å€‘æ›´æ·±å…¥åœ°ç†è§£èƒƒç™Œçš„ç™¼å±•éç¨‹ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—æ–¹æ³•ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œé€²ä¸€æ­¥çš„å¯¦é©—é©—è­‰äº†åƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œå¾è€Œæ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± èƒƒç™Œçš„æ½›åœ¨æ–°å°æ‰‹ï¼šè˜¿è””ç¡«ç´ ï¼ä½ çŸ¥é“å—ï¼Ÿèƒƒç™Œä»ç„¶æ˜¯å…¨çƒå¥åº·çš„ä¸€å¤§å¨è„…ï¼Œæ²»ç™‚é¸æ“‡å»ä¸å¤šã€‚æœ€è¿‘çš„ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°äº†å¸Œæœ›ï¼Œè˜¿è””ç¡«ç´ ï¼Œé€™ç¨®ä¾†è‡ªè˜¿è””çš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½åœ¨æŠ—ç™Œæ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºã€‚ç ”ç©¶äººå“¡é€²è¡Œäº†å„ç¨®å¯¦é©—ï¼Œæƒ³è¦æ­ç¤ºå®ƒçš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚é€éåŸºå› åˆ†æï¼Œä»–å€‘æ‰¾åˆ°äº†èˆ‡è˜¿è””ç¡«ç´ æœ‰é—œçš„ç‰¹å®šRNAï¼Œé€™å¯èƒ½æ˜¯è˜¿è””ç¡«ç´ ç™¼æ®ä½œç”¨çš„é—œéµã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé‚„èƒ½é™ä½æŸç¨®RNAçš„è¡¨é”ï¼Œé€™ç¨®RNAçš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚ç•¶é€™ç¨®RNAè¢«æŠ‘åˆ¶æ™‚ï¼Œç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºèƒƒç™Œæ²»ç™‚çš„æ–°é¶é»ï¼\n\nâœ¨ é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ã€‚\n2. ç ”ç©¶æ­ç¤ºäº†èˆ‡è˜¿è””ç¡«ç´ ç›¸é—œçš„RNAï¼Œå¯èƒ½å½±éŸ¿æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n3. è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic with a light background illustrating the effects of sulforaphane on gastric cancer. Include simplified icons representing broccoli and sulforaphane, as well as simplified figures of human cells. Use arrows or flow lines to depict the experimental process. Add a section labeled 'Key Results' showing the protective effects and changes observed, such as reduced cell proliferation and migration.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„æ½›åœ¨è¼”åŠ©ç™‚æ³•ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œå¦‚é’èŠ±æ¤°èœã€‚é›–ç„¶ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼å°‹æ±‚æœ‰æ•ˆæ²»ç™‚æ–¹æ¡ˆçš„å®¶åº­ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼è‡ªé–‰ç—‡çš„æ²»ç™‚é¸æ“‡æœ‰é™ï¼Œé€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é£²é£Ÿè£œå……æ–¹é¢ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœåŠå…¶èˆ‡ç”Ÿç‰©æ¨™è¨˜çš„é—œè¯ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¯èƒ½è§£é‡‹äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„æ½›åœ¨è¼”åŠ©ç™‚æ³•ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œå¦‚é’èŠ±æ¤°èœã€‚é›–ç„¶ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰æœ‰æ­£é¢å½±éŸ¿ï¼Œé€™å°æ–¼å°‹æ±‚æœ‰æ•ˆæ²»ç™‚æ–¹æ¡ˆçš„å®¶åº­ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼è‡ªé–‰ç—‡çš„æ²»ç™‚é¸æ“‡æœ‰é™ï¼Œé€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é£²é£Ÿè£œå……æ–¹é¢ã€‚\n\nç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœåŠå…¶èˆ‡ç”Ÿç‰©æ¨™è¨˜çš„é—œè¯ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¯èƒ½è§£é‡‹äº†è˜¿è””ç¡«ç´ çš„æŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›æä¾›äº†æ”¯æŒï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ä½ çŸ¥é“é’èŠ±æ¤°èœä¸åªæ˜¯å¥½åƒçš„è”¬èœï¼Œé‚„å¯èƒ½å°è‡ªé–‰ç—‡æœ‰å¹«åŠ©å—ï¼Ÿæœ€è¿‘ä¸€é …ç ”ç©¶å¼•èµ·äº†å¤§å®¶çš„é—œæ³¨ï¼Œå› ç‚ºå®ƒæ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œé€™ç¨®æˆåˆ†ä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘çš„è”¬èœä¸­ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä¸¦ä¸”äº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\né€™é …ç ”ç©¶å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†å…­é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æ¶‰åŠ333ååƒèˆ‡è€…ã€‚ä»–å€‘ä½¿ç”¨äº†å¤šç¨®ç§‘å­¸æ–¹æ³•ä¾†åˆ†æè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚æœ€çµ‚ï¼Œç ”ç©¶ç™¼ç¾ç¶“é4åˆ°10é€±çš„è£œå……ï¼Œåƒèˆ‡è€…çš„ç¤¾äº¤åæ‡‰å¾—åˆ†é¡¯è‘—æ”¹å–„ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æå‡ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æ²’æœ‰ç™¼ç¾æ˜é¡¯çš„å‰¯ä½œç”¨ã€‚\n\né€™äº›çµæœè®“äººå°è˜¿è””ç¡«ç´ ä½œç‚ºè‡ªé–‰ç—‡è¼”åŠ©ç™‚æ³•çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„æ•ˆæœã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. ç ”ç©¶é¡¯ç¤ºåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰ä¸Šå¾—åˆ†æé«˜ã€‚\n3. ç›®å‰æœªç™¼ç¾æ˜é¡¯çš„å‰¯ä½œç”¨ï¼Œä»éœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on sulforaphane and autism. Include simple icons representing broccoli and sulforaphane, simplified figures of participants (people), arrows or flow lines indicating the experimental steps, and a section highlighting 'Main Results' with bullet points showing improvement in social responses and absence of significant side effects.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„é ˜åŸŸã€‚ç§»æ¤æ‚£è€…å¸¸å¸¸é¢è‡¨æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½å°æ”¹å–„ç§»æ¤å¾Œçš„å…ç–«åæ‡‰æœ‰å¹«åŠ©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å¢å¼·ç§»æ¤çš„æˆåŠŸç‡ï¼Œä¸¦æ¸›å°‘æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç§»æ¤å¾Œæ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤ç‰©å­˜æ´»æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚ç”±æ–¼æ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ç§»æ¤æ‚£è€…å¸¸è¦‹çš„å•é¡Œï¼Œå› æ­¤ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œå¯èƒ½ç‚ºæ”¹å–„ç§»æ¤çµæœæä¾›æ–°çš„æ€è·¯å’Œæ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œç‰¹åˆ¥æ˜¯å°‡çš®è†šç§»æ¤åˆ°ä¸åŒåŸºå› å‹çš„å°é¼ èº«ä¸Šã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼ç§»æ¤æ‰‹è¡“ä¸­ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°éª¨é«“ä¾†æºçš„æ¨¹çªç´°èƒé€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä¸¦è§€å¯Ÿäº†ä¸åŒè™•ç†ä¸‹çš„ç§»æ¤ç‰©å­˜æ´»æƒ…æ³ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ æœ‰æ•ˆè©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† è™•ç†å¾Œï¼Œç§»æ¤çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤ç‰©å­˜æ´»ç‡ï¼Œé¡¯è‘—é«˜æ–¼æœªè™•ç†çš„å°é¼ ï¼ˆ100%ç§»æ¤ç‰©åœ¨ç¬¬9å¤©å¤±æ•—ï¼‰ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ ï¼Œå…¶çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„ç ”ç©¶å’Œæ¢ç´¢ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å™¨å®˜ç§»æ¤çš„é ˜åŸŸã€‚ç§»æ¤æ‚£è€…å¸¸å¸¸é¢è‡¨æ€¥æ€§æ’æ–¥åæ‡‰çš„é¢¨éšªï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘æ¤ç‰©ä¸­çš„æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½å°æ”¹å–„ç§»æ¤å¾Œçš„å…ç–«åæ‡‰æœ‰å¹«åŠ©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å¢å¼·ç§»æ¤çš„æˆåŠŸç‡ï¼Œä¸¦æ¸›å°‘æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç§»æ¤å¾Œæ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤ç‰©å­˜æ´»æ–¹é¢çš„æ½›åœ¨ä½œç”¨ã€‚ç”±æ–¼æ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ç§»æ¤æ‚£è€…å¸¸è¦‹çš„å•é¡Œï¼Œå› æ­¤ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œå¯èƒ½ç‚ºæ”¹å–„ç§»æ¤çµæœæä¾›æ–°çš„æ€è·¯å’Œæ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œç‰¹åˆ¥æ˜¯å°‡çš®è†šç§»æ¤åˆ°ä¸åŒåŸºå› å‹çš„å°é¼ èº«ä¸Šã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„ç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼ç§»æ¤æ‰‹è¡“ä¸­ã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°éª¨é«“ä¾†æºçš„æ¨¹çªç´°èƒé€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä¸¦è§€å¯Ÿäº†ä¸åŒè™•ç†ä¸‹çš„ç§»æ¤ç‰©å­˜æ´»æƒ…æ³ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ æœ‰æ•ˆè©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† è™•ç†å¾Œï¼Œç§»æ¤çš„å°é¼ åœ¨14å¤©å…§æœ‰80%çš„ç§»æ¤ç‰©å­˜æ´»ç‡ï¼Œé¡¯è‘—é«˜æ–¼æœªè™•ç†çš„å°é¼ ï¼ˆ100%ç§»æ¤ç‰©åœ¨ç¬¬9å¤©å¤±æ•—ï¼‰ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ ï¼Œå…¶çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ‡‰ç”¨æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„ç ”ç©¶å’Œæ¢ç´¢ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©çš„å¤©ç„¶æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°æ–¼å™¨å®˜ç§»æ¤æœ‰æ½›åœ¨çš„å¥½è™•ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç§»æ¤å¾Œçš„æ€¥æ€§æ’æ–¥åæ‡‰ã€‚ç°¡å–®ä¾†èªªï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ç§»æ¤æ‚£è€…å¸¸è¦‹çš„å•é¡Œï¼Œæœƒå½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œé–‹ç™¼äº†ä¸€ç¨®å«æœ‰è˜¿è””ç¡«ç´ çš„æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ‰‹è¡“ä¸­ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† å¾Œï¼Œå°é¼ çš„ç§»æ¤ç‰©åœ¨14å¤©å…§æœ‰80%çš„å­˜æ´»ç‡ï¼Œé€™æ¯”æœªè™•ç†çš„å°é¼ ï¼ˆ9å¤©å°±å¤±æ•—äº†ï¼‰è¦å¥½å¾—å¤šï¼æ­¤å¤–ï¼Œæ¥å—è™•ç†çš„å°é¼ ç‚ç—‡ç´°èƒæ•¸é‡ä¹Ÿè¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç§»æ¤å¾Œçš„å…ç–«åæ‡‰ã€‚\n2. ç ”ç©¶é¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„æ°´å‡è† èƒ½æé«˜ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚\n3. æ¸›å°‘ç‚ç—‡ç´°èƒæ•¸é‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å»¶ç·©æ’æ–¥åæ‡‰ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å……æ»¿æœŸå¾…ï¼",
    "image_prompt": "Create a flat design infographic that visually explains the experiment and main results of the study on sulforaphane. Include simplified illustrations of broccoli or a representation of sulforaphane, experimental subjects like mice or cells, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting the protective effects and changes observed, all on a light or white background with soft colors.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œä¸¦å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²å¸¶ä¾†å•Ÿç¤ºã€‚éš¨è‘—å°é€™ç¨®åŒ–åˆç‰©çš„ç ”ç©¶ä¸æ–·å¢åŠ ï¼Œäº†è§£å…¶å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œç™¼å±•ï¼Œå°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å¯èƒ½æœƒæœ‰é‡è¦çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨ç™Œç—‡é€™ç¨®è¤‡é›œç–¾ç—…çš„ç®¡ç†ä¸Šã€‚",
    "para2": "é€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©å­¸éç¨‹ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›åŠå…¶æ©Ÿåˆ¶ã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›æ–¹æ³•æœ‰åŠ©æ–¼æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å¯èƒ½å°æŠ—ç™Œç—‡æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šè¡¨æ˜è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºå®šå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜å¦‚ä½•èˆ‡ç¾ä»£é†«å­¸ç›¸çµåˆï¼Œç‚ºæœªä¾†çš„è—¥ç‰©é–‹ç™¼æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œä¸¦å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²å¸¶ä¾†å•Ÿç¤ºã€‚éš¨è‘—å°é€™ç¨®åŒ–åˆç‰©çš„ç ”ç©¶ä¸æ–·å¢åŠ ï¼Œäº†è§£å…¶å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œç™¼å±•ï¼Œå°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å¯èƒ½æœƒæœ‰é‡è¦çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯åœ¨ç™Œç—‡é€™ç¨®è¤‡é›œç–¾ç—…çš„ç®¡ç†ä¸Šã€‚\n\né€™ç¯‡ç¶œè¿°çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©å­¸éç¨‹ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ã€‚é€™äº›å•é¡Œçš„æ¢è¨æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›åŠå…¶æ©Ÿåˆ¶ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€éæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªã€‚ç ”ç©¶è€…é‚„æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œè˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„å”åŒæ•ˆæ‡‰ï¼Œé€™äº›æ–¹æ³•æœ‰åŠ©æ–¼æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å¯èƒ½å°æŠ—ç™Œç—‡æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šè¡¨æ˜è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºå®šå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†å‚³çµ±è—¥ç†çŸ¥è­˜å¦‚ä½•èˆ‡ç¾ä»£é†«å­¸ç›¸çµåˆï¼Œç‚ºæœªä¾†çš„è—¥ç‰©é–‹ç™¼æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡è—è‘—ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å—ï¼Ÿé€™å°±æ˜¯è˜¿è””ç¡«ç´ ï¼ˆSulforaphaneï¼‰ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©å¯èƒ½å°ç™Œç—‡æ²»ç™‚æœ‰æ½›åœ¨çš„å¹«åŠ©ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†äº†è§£ä¸€ä¸‹å§ï¼\n\né€™ç¯‡ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å„ç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œå½±éŸ¿å®ƒå€‘çš„ç”Ÿé•·å’Œç™¼å±•ã€‚ç ”ç©¶è€…å€‘é€éæ–‡ç»å›é¡§ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œåƒæ˜¯ç‚ç—‡ä»‹è³ªå’Œä¸€äº›ç‰¹æ®Šè›‹ç™½è³ªï¼Œä¸¦ä¸”ä¹Ÿè€ƒæ…®äº†ç´ç±³æŠ€è¡“çš„æ‡‰ç”¨ï¼Œé€™å¯èƒ½æœƒæå‡å…¶ç™‚æ•ˆã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å¯èƒ½å°æŠ—ç™Œç—‡æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºå®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ã€‚  \n2. ç ”ç©¶åˆ†æäº†å®ƒå°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œä¸¦æ¢è¨äº†ç´ç±³æŠ€è¡“çš„æ‡‰ç”¨ã€‚  \n3. é›–ç„¶æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚  \n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç ”ç©¶æˆæœå§ï¼",
    "image_prompt": "Create an infographic that explains the experimental approach and main findings of a study on sulforaphane. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, or cells), arrows or flow lines to indicate experimental steps, and a section labeled 'Main Findings' that highlights protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ åœ¨ç²¾ç¥ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯æ€è¦ºå¤±èª¿ç—‡ï¼ˆç²¾ç¥åˆ†è£‚ç—‡ï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆçš„åˆæ­¥è¦‹è§£ã€‚æ€è¦ºå¤±èª¿ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€è€ƒã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚é›–ç„¶é€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ï¼Œé€™äº›çµæœéœ€è¦è¬¹æ…è§£è®€ã€‚é€™æé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½å°å¿ƒç†å¥åº·æœ‰å½±éŸ¿ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ€è¦ºå¤±èª¿ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œæ˜¯å¦èƒ½æ”¹å–„æ€è¦ºå¤±èª¿ç—‡æ‚£è€…çš„ç—‡ç‹€ã€‚é€™æ˜¯ç¬¬ä¸€å€‹ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç²¾ç¥ç–¾ç—…ä¸­çš„æ½›åœ¨æ²»ç™‚ä½œç”¨ï¼Œä¸¦è©•ä¼°å…¶å°æ‚£è€…çš„å½±éŸ¿ã€‚",
    "para3": "é€™é …ç ”ç©¶é€²è¡Œäº†ä¸€ç³»åˆ—éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œå…±ç´å…¥äº†369åæ€è¦ºå¤±èª¿ç—‡æ‚£è€…ã€‚ç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦é¸æ“‡äº†ç¬¦åˆæ¢ä»¶çš„ç ”ç©¶é€²è¡Œåˆ†æã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬æ€è¦ºå¤±èª¿ç—‡ç‹€çš„è®ŠåŒ–ï¼Œä½¿ç”¨çš„é‡è¡¨åŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰åŠå…¶å­é‡è¡¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æŒ‡æ¨™å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœ€æ–°çš„éš¨è¨ªä¸­å°PANSSç¸½åˆ†æˆ–æ­£æ€§ç—‡ç‹€å¾—åˆ†ä¸¦æœªé¡¯è‘—æ”¹å–„ï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸å¾—åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œç„¶è€ŒèªçŸ¥æ–¹é¢ä¸¦æœªè§€å¯Ÿåˆ°ä»»ä½•å¥½è™•ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æŒ‡æ¨™æœ‰é¡¯è‘—çš„é™ä½ä½œç”¨ï¼ŒåŒ…æ‹¬ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šçš„æœ‰é™æ€§å’Œç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ åœ¨ç²¾ç¥ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯æ€è¦ºå¤±èª¿ç—‡ï¼ˆç²¾ç¥åˆ†è£‚ç—‡ï¼‰ä¸­çš„æ½›åœ¨ç™‚æ•ˆçš„åˆæ­¥è¦‹è§£ã€‚æ€è¦ºå¤±èª¿ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€è€ƒã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚é›–ç„¶é€™é …ç ”ç©¶çš„çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™ï¼Œé€™äº›çµæœéœ€è¦è¬¹æ…è§£è®€ã€‚é€™æé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½å°å¿ƒç†å¥åº·æœ‰å½±éŸ¿ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œå®‰å…¨æ€§ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ€è¦ºå¤±èª¿ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œæ˜¯å¦èƒ½æ”¹å–„æ€è¦ºå¤±èª¿ç—‡æ‚£è€…çš„ç—‡ç‹€ã€‚é€™æ˜¯ç¬¬ä¸€å€‹ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç²¾ç¥ç–¾ç—…ä¸­çš„æ½›åœ¨æ²»ç™‚ä½œç”¨ï¼Œä¸¦è©•ä¼°å…¶å°æ‚£è€…çš„å½±éŸ¿ã€‚\n\né€™é …ç ”ç©¶é€²è¡Œäº†ä¸€ç³»åˆ—éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTï¼‰ï¼Œå…±ç´å…¥äº†369åæ€è¦ºå¤±èª¿ç—‡æ‚£è€…ã€‚ç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦é¸æ“‡äº†ç¬¦åˆæ¢ä»¶çš„ç ”ç©¶é€²è¡Œåˆ†æã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬æ€è¦ºå¤±èª¿ç—‡ç‹€çš„è®ŠåŒ–ï¼Œä½¿ç”¨çš„é‡è¡¨åŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰åŠå…¶å­é‡è¡¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æŒ‡æ¨™å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœ€æ–°çš„éš¨è¨ªä¸­å°PANSSç¸½åˆ†æˆ–æ­£æ€§ç—‡ç‹€å¾—åˆ†ä¸¦æœªé¡¯è‘—æ”¹å–„ï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸å¾—åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œç„¶è€ŒèªçŸ¥æ–¹é¢ä¸¦æœªè§€å¯Ÿåˆ°ä»»ä½•å¥½è™•ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æŒ‡æ¨™æœ‰é¡¯è‘—çš„é™ä½ä½œç”¨ï¼ŒåŒ…æ‹¬ä½å¯†åº¦è„‚è›‹ç™½ï¼ˆLDLï¼‰ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šçš„æœ‰é™æ€§å’Œç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¿ƒç†å¥åº·æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ€è¦ºå¤±èª¿ç—‡ï¼ˆä¹Ÿå°±æ˜¯ç²¾ç¥åˆ†è£‚ç—‡ï¼‰æ‚£è€…ï¼Œæƒ³çœ‹çœ‹é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œæ˜¯å¦èƒ½æ”¹å–„ä»–å€‘çš„ç—‡ç‹€ã€‚ç ”ç©¶è€…å€‘é€²è¡Œäº†ä¸€ç³»åˆ—éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±ç´å…¥äº†369åæ‚£è€…ï¼Œä¸¦è©•ä¼°äº†ä»–å€‘çš„ç—‡ç‹€è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œé›–ç„¶åœ¨æŸäº›ç—‡ç‹€ä¸Šæ²’æœ‰é¡¯è‘—æ”¹å–„ï¼Œä½†åœ¨è² æ€§ç—‡ç‹€ä¸Šæœ‰è¼•å¾®çš„æ”¹å–„ï¼Œè€Œä¸”å°æ–¼ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼ˆåƒæ˜¯è†½å›ºé†‡ï¼‰ä¹Ÿæœ‰é™ä½çš„æ•ˆæœã€‚é€™è®“æˆ‘å€‘çœ‹åˆ°ï¼Œé£²é£Ÿä¸­çš„ä¸€äº›æˆåˆ†æˆ–è¨±æœƒå½±éŸ¿å¿ƒç†å¥åº·ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ åœ¨æ€è¦ºå¤±èª¿ç—‡çš„ç ”ç©¶ä¸­é¡¯ç¤ºå‡ºæ½›åŠ›ã€‚\n2. åœ¨12é€±çš„è§€å¯Ÿä¸­ï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚\n3. å°ä»£è¬æŒ‡æ¨™æœ‰é¡¯è‘—é™ä½ä½œç”¨ï¼Œä½†ä»éœ€è¬¹æ…è§£è®€ã€‚",
    "image_prompt": "Create a flat design infographic that explains the study on sulforaphane and its effects on schizophrenia. The background should be white or light-colored with soft color tones. Include simple icons representing broccoli (for sulforaphane), simplified human figures as experimental subjects, and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' that highlights the mild improvement in negative symptoms and the reduction in metabolic indicators.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ€è¦ºå¤±èª¿ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå…ˆå…†å­ç™‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å…ˆå…†å­ç™‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ç–¾ç—…ï¼Œæœƒå°è‡´æ¯é«”é«˜è¡€å£“å’Œèƒå…’ç”Ÿé•·å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œé€™å°æ–¼é é˜²å…ˆå…†å­ç™‡çš„æœ‰å®³å½±éŸ¿ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„æ–¹å‘ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨å¦Šå¨ æœŸé–“é©ç•¶æ”å–è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°æ¯é«”å’Œèƒå…’çš„å¥åº·ç”¢ç”Ÿæ­£é¢å½±éŸ¿ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢å’Œç ”ç©¶ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½åœ¨å¦Šå¨ æœŸé–“é€éæ¯é«”çš„è¡€æ¶²å’Œæ¯ä¹³å‚³éçµ¦èƒå…’ï¼Œé€™å°æ–¼äº†è§£å…¶åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ‡‰ç”¨æ½›åŠ›è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶çš„çµæœå°‡æœ‰åŠ©æ–¼æœªä¾†å°æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„è¦‹è§£ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶å°è±¡ç‚º8ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦çš„å¦Šå¨ é€±æ•¸å‡è¶…é37é€±ï¼Œä¸¦ä¸”åœ¨æ‰‹è¡“å‰ç°½ç½²äº†çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘å£æœçš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼ˆEnduraCellï¼‰ï¼Œç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚æ‰‹è¡“å‰å¾Œï¼Œç ”ç©¶åœ˜éšŠæ”¶é›†äº†å­•å©¦çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–ä¾‹è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰è¼•å¾®å¢åŠ ï¼Œä½†æ•´é«”ä¸Šï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡åœ¨æ”å–è˜¿è””ç¡«ç´ å¾Œä¸¦æœªé¡¯è‘—æ”¹è®Šã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå…ˆå…†å­ç™‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å…ˆå…†å­ç™‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ç–¾ç—…ï¼Œæœƒå°è‡´æ¯é«”é«˜è¡€å£“å’Œèƒå…’ç”Ÿé•·å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œé€™å°æ–¼é é˜²å…ˆå…†å­ç™‡çš„æœ‰å®³å½±éŸ¿ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„æ–¹å‘ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨å¦Šå¨ æœŸé–“é©ç•¶æ”å–è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°æ¯é«”å’Œèƒå…’çš„å¥åº·ç”¢ç”Ÿæ­£é¢å½±éŸ¿ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢å’Œç ”ç©¶ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒæ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½åœ¨å¦Šå¨ æœŸé–“é€éæ¯é«”çš„è¡€æ¶²å’Œæ¯ä¹³å‚³éçµ¦èƒå…’ï¼Œé€™å°æ–¼äº†è§£å…¶åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ‡‰ç”¨æ½›åŠ›è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶çš„çµæœå°‡æœ‰åŠ©æ–¼æœªä¾†å°æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„è¦‹è§£ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶å°è±¡ç‚º8ä½è¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å¥åº·å­•å©¦ï¼Œé€™äº›å­•å©¦çš„å¦Šå¨ é€±æ•¸å‡è¶…é37é€±ï¼Œä¸¦ä¸”åœ¨æ‰‹è¡“å‰ç°½ç½²äº†çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘å£æœçš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼ˆEnduraCellï¼‰ï¼Œç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚æ‰‹è¡“å‰å¾Œï¼Œç ”ç©¶åœ˜éšŠæ”¶é›†äº†å­•å©¦çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œå­•å©¦å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–ä¾‹è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å‘¨é‚Šèˆ’å¼µå£“æœ‰è¼•å¾®å¢åŠ ï¼Œä½†æ•´é«”ä¸Šï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡åœ¨æ”å–è˜¿è””ç¡«ç´ å¾Œä¸¦æœªé¡¯è‘—æ”¹è®Šã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½å°å­•å©¦å’Œèƒå…’çš„å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼é€™æ˜¯ä¸€é …æ–°ç ”ç©¶çš„ç™¼ç¾ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹å§ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆä¹Ÿå°±æ˜¯å…ˆå…†å­ç™‡ï¼‰ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚å…ˆå…†å­ç™‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ç–¾ç—…ï¼Œæœƒè®“å­•å©¦å‡ºç¾é«˜è¡€å£“ï¼Œç”šè‡³å½±éŸ¿èƒå…’çš„ç”Ÿé•·ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œé€™æ¨£æˆ–è¨±èƒ½å¹«åŠ©æ”¹å–„é€™ç¨®æƒ…æ³ã€‚\n\nåœ¨é€™é …å¯¦é©—ä¸­ï¼Œ8ä½è¨ˆåŠƒå‰–è…¹ç”¢çš„å¥åº·å­•å©¦åƒèˆ‡äº†ç ”ç©¶ã€‚å¥¹å€‘åœ¨æ‰‹è¡“å‰æœç”¨äº†å«æœ‰è˜¿è””ç¡«ç´ çš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œç„¶å¾Œç ”ç©¶åœ˜éšŠæ”¶é›†äº†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å­•å©¦çš„è¡€æ¶²ã€è‡å¸¶è¡€ï¼ˆèƒå…’çš„è¡€æ¶²ï¼‰å’Œæ¯ä¹³ä¸­éƒ½æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–ä¾‹è­‰æ“šï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼é›–ç„¶å­•å©¦çš„è¡€å£“æœ‰è¼•å¾®è®ŠåŒ–ï¼Œä½†æ•´é«”ä¸Šä¸¦æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚\n\nğŸ”‘ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡æœ‰ä¿è­·ä½œç”¨ã€‚\n2. ç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚\n3. é€™ç‚ºæœªä¾†ç ”ç©¶æä¾›äº†æ–°æ–¹å‘ï¼Œå€¼å¾—æŒçºŒé—œæ³¨ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane. Use a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of the subjects (like people), arrows or lines to show the experimental steps, and a section labeled 'Main Results' highlighting the protective effects and transfer of sulforaphane from mother to fetus.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ã€‚å†çŒæ³¨æ²»ç™‚é›–ç„¶èƒ½å¤ æ¢å¾©è¡€æµï¼Œä½†å¸¸å¸¸æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶äººå“¡æ¢ç´¢äº†è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©çš„æ½›åŠ›ï¼Œé€™äº›åŒ–åˆç‰©ä»¥å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§è€Œèåï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œæ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚é€™äº›ç™¼ç¾å¯èƒ½å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚å’Œé é˜²ç­–ç•¥æœ‰é‡è¦å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œå†çŒæ³¨æå‚·ä¸­çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„ä¸»è¦å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨é€™äº›åŒ–åˆç‰©ä¾†æ¸›å°‘ç”±ç¼ºè¡€å†çŒæ³¨å¼•èµ·çš„æå‚·ï¼Œä¸¦æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆã€‚é€éå°è˜¿è””ç¡«ç´ çš„çµæ§‹é€²è¡Œæ”¹è‰¯ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè¡€ç®¡ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦é¸æ“‡äº†å…¶ä¸­ä¸€ç¨®åç‚º3gçš„åŒ–åˆç‰©é€²è¡Œæ·±å…¥ç ”ç©¶ã€‚å¯¦é©—å°è±¡ç‚ºå¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œé‡ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­çš„è€å—æ€§ï¼Œä¸¦ä½¿ç”¨åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†äº†è§£å…¶åˆ†å­ç‰¹æ€§åŠå…¶å°Nrf2/Keap1é€šè·¯çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œé™ä½å¹…åº¦é”24.5%ï¼Œä¸¦ä¸”åœ¨ä¿ƒé€²æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿå’Œé™ä½è…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œä¸Šä¹Ÿæœ‰è‰¯å¥½æ•ˆæœã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œé¡¯ç¤ºå‡ºæ¯”å‚³çµ±è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´é«˜çš„æ•ˆèƒ½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ã€‚å†çŒæ³¨æ²»ç™‚é›–ç„¶èƒ½å¤ æ¢å¾©è¡€æµï¼Œä½†å¸¸å¸¸æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶äººå“¡æ¢ç´¢äº†è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©çš„æ½›åŠ›ï¼Œé€™äº›åŒ–åˆç‰©ä»¥å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§è€Œèåï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œæ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚é€™äº›ç™¼ç¾å¯èƒ½å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚å’Œé é˜²ç­–ç•¥æœ‰é‡è¦å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œå†çŒæ³¨æå‚·ä¸­çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„ä¸»è¦å•é¡Œæ˜¯å¦‚ä½•åˆ©ç”¨é€™äº›åŒ–åˆç‰©ä¾†æ¸›å°‘ç”±ç¼ºè¡€å†çŒæ³¨å¼•èµ·çš„æå‚·ï¼Œä¸¦æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆã€‚é€éå°è˜¿è””ç¡«ç´ çš„çµæ§‹é€²è¡Œæ”¹è‰¯ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè¡€ç®¡ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦é¸æ“‡äº†å…¶ä¸­ä¸€ç¨®åç‚º3gçš„åŒ–åˆç‰©é€²è¡Œæ·±å…¥ç ”ç©¶ã€‚å¯¦é©—å°è±¡ç‚ºå¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œç ”ç©¶æ–¹æ³•åŒ…æ‹¬æ¸¬é‡æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œé‡ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­çš„è€å—æ€§ï¼Œä¸¦ä½¿ç”¨åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†äº†è§£å…¶åˆ†å­ç‰¹æ€§åŠå…¶å°Nrf2/Keap1é€šè·¯çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œé™ä½å¹…åº¦é”24.5%ï¼Œä¸¦ä¸”åœ¨ä¿ƒé€²æ°®æ°§åŒ–ç‰©ç”¢ç”Ÿå’Œé™ä½è…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œä¸Šä¹Ÿæœ‰è‰¯å¥½æ•ˆæœã€‚æ­¤å¤–ï¼Œ3gåœ¨æŠ—è…«ç˜¤æ´»æ€§æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œé¡¯ç¤ºå‡ºæ¯”å‚³çµ±è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´é«˜çš„æ•ˆèƒ½ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿåœ¨é¢å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡æ™‚ï¼Œæœƒé­é‡åˆ°ä¸€ç¨®å«åšç¼ºè¡€å†çŒæ³¨æå‚·çš„å•é¡Œã€‚é€™æ˜¯ä»€éº¼æ„æ€å‘¢ï¼Ÿç°¡å–®ä¾†èªªï¼Œå°±æ˜¯é›–ç„¶é†«ç™‚æŠ€è¡“å¯ä»¥å¹«åŠ©æ¢å¾©è¡€æµï¼Œä½†é€™å€‹éç¨‹æœ‰æ™‚æœƒé€ æˆæ›´å¤šçš„å‚·å®³ï¼Œå°¤å…¶æ˜¯ç”±æ–¼éå¤šçš„æ´»æ€§æ°§ï¼ˆROSï¼‰é€ æˆçš„ã€‚æœ€è¿‘ï¼Œæœ‰ç ”ç©¶è€…é–‹å§‹é—œæ³¨ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œå®ƒä»¥æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–è‘—ç¨±ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚ é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ‰¾å‡ºè˜¿è””ç¡«ç´ åŠå…¶æ”¹è‰¯ç‰ˆçš„åŒ–åˆç‰©ï¼Œçœ‹çœ‹å®ƒå€‘èƒ½å¦æ¸›å°‘é€™ç¨®æå‚·ã€‚ç ”ç©¶è€…åˆæˆäº†å¤šç¨®è¡ç”Ÿç‰©ï¼Œä¸¦é¸æ“‡äº†å…¶ä¸­ä¸€ç¨®åç‚º3gçš„åŒ–åˆç‰©é€²è¡Œæ·±å…¥ç ”ç©¶ã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘æ¸¬é‡äº†æ´»æ€§æ°§çš„æ°´å¹³ã€æ°®æ°§åŒ–ç‰©çš„ç”¢ç”Ÿä»¥åŠè…«ç˜¤å£æ­»å› å­Î±çš„åˆ†æ³Œï¼Œçµæœé¡¯ç¤ºï¼Œ3gåœ¨é™ä½æ´»æ€§æ°§æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œç”šè‡³è¶…éäº†ä¸€äº›å‚³çµ±è—¥ç‰©çš„æ•ˆæœã€‚ é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚å’Œé é˜²æœ‰äº†æ–°çš„å¸Œæœ›ï¼\n\nâœ¨ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿå†çŒæ³¨æå‚·ã€‚\n2. åŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ–¹é¢æ•ˆæœé¡¯è‘—ã€‚\n3. 3gçš„æŠ—è…«ç˜¤æ´»æ€§è¶…éå‚³çµ±è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on a compound called sulforaphane. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like cells, and arrows or flow lines to represent the experimental steps. Add a section that highlights the main results, such as protective effects and changes in levels of reactive oxygen species (ROS) and nitric oxide production.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒå…§çš„æ°§åŒ–é‚„åŸå¹³è¡¡éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½ä¸­å’Œè‡ªç”±åŸºï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ç‰©ç¨®ï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½¿ç”¨ä¸Šï¼Œå› ç‚ºå®ƒå€‘èƒ½å¹«åŠ©æ¸›å°‘æ°§åŒ–æå‚·ï¼Œé€²è€Œå¯èƒ½é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·ç´°èƒï¼Œä¿ƒé€²å¥åº·ï¼Œç”šè‡³åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå¯èƒ½å°æŠ—è€åŒ–æˆ–æ…¢æ€§ç–¾ç—…çš„ç™¼å±•æœ‰å¹«åŠ©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—ï¼ˆesculin, ESCï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼æ ¸å› å­ç´…è¡€çƒ2ç›¸é—œå› å­2ï¼ˆNrf2ï¼‰çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ç´°èƒä¿è­·åŸºå› ï¼Œä»¥æŠµæŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …æ¯”è¼ƒï¼Œäº†è§£é€™å…©ç¨®åŒ–åˆç‰©åœ¨ä¿ƒé€²æŠ—æ°§åŒ–åæ‡‰æ–¹é¢çš„å·®ç•°èˆ‡ç›¸ä¼¼ä¹‹è™•ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥è™•ç†è˜‡å…‹æ—ï¼ˆ100 Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40 Î¼Mï¼‰ï¼Œä¸¦è¨­ç½®å°ç…§çµ„ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€è°·èƒ±ç”˜è‚½Sè½‰ç§»é…¶ï¼ˆGSTï¼‰ã€è°·èƒ±ç”˜è‚½éæ°§åŒ–é…¶ï¼ˆGPxï¼‰ã€éæ°§åŒ–æ°«é…¶ï¼ˆCATï¼‰å’Œé‚„åŸå‹è°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰çš„æ°´å¹³ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†ç¢ºå®šæŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”æ°´å¹³ï¼Œä¸¦é€éç´°èƒæ ¸/ç´°èƒè³ªåˆ†é¤¾å’Œå…¨èº«å…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSTã€GPxã€CATï¼‰ï¼Œå…¶æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œè˜‡å…‹æ—é‚„å¢å¼·äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé€™äº›åŸºå› åŒ…æ‹¬nrf2ã€gstp1ã€hmox1aç­‰ã€‚æŠ—æ°§åŒ–è›‹ç™½Nrf2ã€Gstp1ã€Catå’ŒSod2åœ¨è˜‡å…‹æ—è™•ç†çµ„ä¸­ä¹Ÿæœ‰ä¸Šèª¿ã€‚æœ€çµ‚ï¼Œç ”ç©¶ç¢ºèªäº†åœ¨è˜¿è””ç¡«ç´ å’Œè˜‡å…‹æ—è™•ç†çµ„ä¸­ï¼ŒNrf2çš„æ ¸å®šä½ï¼Œé€™è¡¨æ˜Nrf2æˆåŠŸè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼çš„å¼·æŠ—æ°§åŒ–æ´»æ€§ï¼Œä¸¦ä¸”å¯èƒ½é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒå…§çš„æ°§åŒ–é‚„åŸå¹³è¡¡éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½ä¸­å’Œè‡ªç”±åŸºï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ç‰©ç¨®ï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½¿ç”¨ä¸Šï¼Œå› ç‚ºå®ƒå€‘èƒ½å¹«åŠ©æ¸›å°‘æ°§åŒ–æå‚·ï¼Œé€²è€Œå¯èƒ½é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·ç´°èƒï¼Œä¿ƒé€²å¥åº·ï¼Œç”šè‡³åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå¯èƒ½å°æŠ—è€åŒ–æˆ–æ…¢æ€§ç–¾ç—…çš„ç™¼å±•æœ‰å¹«åŠ©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜‡å…‹æ—ï¼ˆesculin, ESCï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°æ–¼æ ¸å› å­ç´…è¡€çƒ2ç›¸é—œå› å­2ï¼ˆNrf2ï¼‰çš„æ¿€æ´»æ•ˆæœã€‚Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ç´°èƒä¿è­·åŸºå› ï¼Œä»¥æŠµæŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …æ¯”è¼ƒï¼Œäº†è§£é€™å…©ç¨®åŒ–åˆç‰©åœ¨ä¿ƒé€²æŠ—æ°§åŒ–åæ‡‰æ–¹é¢çš„å·®ç•°èˆ‡ç›¸ä¼¼ä¹‹è™•ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥è™•ç†è˜‡å…‹æ—ï¼ˆ100 Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40 Î¼Mï¼‰ï¼Œä¸¦è¨­ç½®å°ç…§çµ„ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€è°·èƒ±ç”˜è‚½Sè½‰ç§»é…¶ï¼ˆGSTï¼‰ã€è°·èƒ±ç”˜è‚½éæ°§åŒ–é…¶ï¼ˆGPxï¼‰ã€éæ°§åŒ–æ°«é…¶ï¼ˆCATï¼‰å’Œé‚„åŸå‹è°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰çš„æ°´å¹³ã€‚æ­¤å¤–ï¼Œé‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†ç¢ºå®šæŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”æ°´å¹³ï¼Œä¸¦é€éç´°èƒæ ¸/ç´°èƒè³ªåˆ†é¤¾å’Œå…¨èº«å…ç–«çµ„ç¹”åŒ–å­¸æ–¹æ³•è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSTã€GPxã€CATï¼‰ï¼Œå…¶æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œè˜‡å…‹æ—é‚„å¢å¼·äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé€™äº›åŸºå› åŒ…æ‹¬nrf2ã€gstp1ã€hmox1aç­‰ã€‚æŠ—æ°§åŒ–è›‹ç™½Nrf2ã€Gstp1ã€Catå’ŒSod2åœ¨è˜‡å…‹æ—è™•ç†çµ„ä¸­ä¹Ÿæœ‰ä¸Šèª¿ã€‚æœ€çµ‚ï¼Œç ”ç©¶ç¢ºèªäº†åœ¨è˜¿è””ç¡«ç´ å’Œè˜‡å…‹æ—è™•ç†çµ„ä¸­ï¼ŒNrf2çš„æ ¸å®šä½ï¼Œé€™è¡¨æ˜Nrf2æˆåŠŸè½‰ç§»åˆ°ç´°èƒæ ¸ä¸­ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜‡å…‹æ—åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ä¼¼çš„å¼·æŠ—æ°§åŒ–æ´»æ€§ï¼Œä¸¦ä¸”å¯èƒ½é€šéKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æ¤ç‰©çš„æˆåˆ†å¯ä»¥å¹«åŠ©æˆ‘å€‘çš„èº«é«”æŠµæŠ—æ°§åŒ–å‚·å®³ï¼Œè®“æˆ‘å€‘æ›´å¥åº·ï¼æœ€è¿‘æœ‰ç ”ç©¶èšç„¦åœ¨å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼šè˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹å®ƒå€‘åœ¨ä¿è­·ç´°èƒæ–¹é¢çš„è¡¨ç¾ã€‚é€™é …ç ”ç©¶ä½¿ç”¨æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œåˆ†æˆä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆé€™å…©ç¨®åŒ–åˆç‰©ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘çš„æŠ—æ°§åŒ–æ•ˆæœã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜‡å…‹æ—èƒ½é¡¯è‘—æå‡æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ï¼Œä¸¦ä¸”é€™å…©è€…éƒ½èƒ½ä¿ƒé€²ç´°èƒå…§çš„ä¿è­·å› å­Nrf2é€²å…¥ç´°èƒæ ¸ï¼Œç™¼æ®ä¿è­·ä½œç”¨ã€‚é€™äº›çµæœè®“æˆ‘å€‘å°æ–¼å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å¢å¼·å¥åº·å……æ»¿æœŸå¾…ï¼\n\nâœ¨é‡é»æ•´ç†ï¼š\n1. è˜‡å…‹æ—å’Œè˜¿è””ç¡«ç´ éƒ½èƒ½å¹«åŠ©æŠµæŠ—æ°§åŒ–å‚·å®³ã€‚\n2. è˜‡å…‹æ—æå‡äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚\n3. ç ”ç©¶æ­ç¤ºäº†Nrf2åœ¨ç´°èƒå…§çš„ä¿è­·æ©Ÿåˆ¶ï¼Œè®“æˆ‘å€‘æ›´äº†è§£å¤©ç„¶æˆåˆ†çš„æ½›åŠ›ï¼",
    "image_prompt": "Create an infographic that visually explains the experiment and main results of a study comparing the antioxidant potential of two natural compounds: esculin and sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of zebrafish or cells as experimental subjects, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as increased antioxidant enzyme activity and the protective effects of these compounds.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™¼ç‚ç›¸é—œç–¾ç—…æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å®ƒçš„æ‡‰ç”¨ã€‚é€éæ”¹è‰¯çš„å‚³éç³»çµ±ï¼Œé€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•é–‹é—¢æ–°çš„å¯èƒ½æ€§ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§ç–¾ç—…çš„ç®¡ç†ä¸Šã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ç³–è‹·çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯ç”¨æ€§å’Œæº¶è§£æ€§ï¼Œä»¥å¢å¼·å…¶åœ¨æ²»ç™‚ç™¼ç‚ç–¾ç—…ä¸­çš„æ½›åŠ›ã€‚é€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼é–‹ç™¼æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦è©•ä¼°å…¶åœ¨å¥åº·ä¾›é«”çš„æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¾å¥åº·ä¾›é«”ä¸­æå–çš„å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSèª˜å°çš„ç™¼ç‚ç’°å¢ƒä¸­ã€‚ç ”ç©¶è€…å°é€™äº›æ¨¹çªç´°èƒé€²è¡Œäº†è˜¿è””ç¡«ç´ ç³–è‹·çš„è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶åœ¨ç™¼ç‚ç‹€æ…‹ä¸‹çš„åæ‡‰ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ ç³–è‹·åœ¨æŠ‘åˆ¶ç™¼ç‚å’Œèª¿ç¯€å…ç–«åæ‡‰æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ¢ç´¢å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œä¸¦ä¸”é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†ç™¼æ®ä½œç”¨ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›ç³–è‹·ä¿ƒé€²äº†è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ äº†IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œä¸¦å¼·èª¿äº†é€™äº›æ”¹è‰¯çš„å‚³éç³»çµ±åœ¨æœªä¾†æ‡‰ç”¨ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™¼ç‚ç›¸é—œç–¾ç—…æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å®ƒçš„æ‡‰ç”¨ã€‚é€éæ”¹è‰¯çš„å‚³éç³»çµ±ï¼Œé€™é …ç ”ç©¶å¸Œæœ›èƒ½å¤ æå‡è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•é–‹é—¢æ–°çš„å¯èƒ½æ€§ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§ç–¾ç—…çš„ç®¡ç†ä¸Šã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ç³–è‹·çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯ç”¨æ€§å’Œæº¶è§£æ€§ï¼Œä»¥å¢å¼·å…¶åœ¨æ²»ç™‚ç™¼ç‚ç–¾ç—…ä¸­çš„æ½›åŠ›ã€‚é€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼é–‹ç™¼æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦è©•ä¼°å…¶åœ¨å¥åº·ä¾›é«”çš„æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å¾å¥åº·ä¾›é«”ä¸­æå–çš„å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSèª˜å°çš„ç™¼ç‚ç’°å¢ƒä¸­ã€‚ç ”ç©¶è€…å°é€™äº›æ¨¹çªç´°èƒé€²è¡Œäº†è˜¿è””ç¡«ç´ ç³–è‹·çš„è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶åœ¨ç™¼ç‚ç‹€æ…‹ä¸‹çš„åæ‡‰ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ ç³–è‹·åœ¨æŠ‘åˆ¶ç™¼ç‚å’Œèª¿ç¯€å…ç–«åæ‡‰æ–¹é¢çš„æ•ˆæœï¼Œä¸¦æ¢ç´¢å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œä¸¦ä¸”é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†ç™¼æ®ä½œç”¨ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›ç³–è‹·ä¿ƒé€²äº†è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ äº†IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„æ•ˆæœï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œä¸¦å¼·èª¿äº†é€™äº›æ”¹è‰¯çš„å‚³éç³»çµ±åœ¨æœªä¾†æ‡‰ç”¨ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€äº›ç¥å¥‡çš„åŒ–åˆç‰©ï¼Œå¯ä»¥å¹«åŠ©æˆ‘å€‘å°æŠ—ç™¼ç‚ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œç™¼ç¾å®ƒåœ¨å¥åº·å’Œé é˜²ç–¾ç—…æ–¹é¢æœ‰å¾ˆå¤§çš„æ½›åŠ›ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ‰¾å‡ºå¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰ã€‚ç ”ç©¶äººå“¡é–‹ç™¼äº†ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦åœ¨å¯¦é©—ä¸­ä½¿ç”¨å¥åº·ä¾›é«”çš„æ¨¹çªç´°èƒï¼Œè§€å¯Ÿå®ƒå€‘åœ¨ç™¼ç‚ç’°å¢ƒä¸­çš„åæ‡‰ã€‚çµæœé¡¯ç¤ºï¼Œé€™ç¨®è˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œä¸¦ä¸”é€šéä¸€å€‹ç‰¹å®šçš„é€”å¾‘ä¾†ç™¼æ®ä½œç”¨ï¼Œé‚„èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·åæ‡‰ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•å……æ»¿æœŸå¾…ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ã€‚\n2. å®ƒé€éç‰¹å®šé€”å¾‘ä¿ƒé€²å…ç–«åæ‡‰ã€‚\n3. æœ‰æ½›åŠ›æˆç‚ºæœªä¾†æ²»ç™‚ç™¼ç‚ç–¾ç—…çš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main findings of a study on a compound called sulforaphane. Use flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to show the experimental steps. Add a section that highlights the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚æ€§ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©å¯èƒ½å…·æœ‰å¤šç¨®è—¥ç”¨åƒ¹å€¼ï¼Œç„¶è€Œé€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æª¢æ¸¬å’Œåˆ©ç”¨é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œç–¾ç—…çš„é é˜²ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°‹æ‰¾éé£Ÿç”¨æ¤ç‰©ä¸­çš„æ½›åœ¨è³‡æºæ–¹é¢ã€‚",
    "para2": "ç ”ç©¶çš„ä¸»é¡Œæ˜¯å¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚é€™äº›åŒ–åˆç‰©åœ¨è¨±å¤šç ”ç©¶ä¸­é¡¯ç¤ºå‡ºæ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†ç”±æ–¼å®ƒå€‘ä¸»è¦å­˜åœ¨æ–¼ç‰¹å®šçš„è”¬èœä¸­ï¼Œé™åˆ¶äº†å…¶æ‡‰ç”¨ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶é—œæ³¨å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä»¥æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€ééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚é€™ç¨®æ–¹æ³•çš„å„ªåŒ–æ¢ä»¶ä¸‹ï¼Œé¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œä½æª¢æ¸¬é™ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ä¹‹é–“ï¼Œæ¨™æº–åå·®å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-è¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨çš„æ–¹æ³•åœ¨æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©å¯èƒ½å…·æœ‰å¤šç¨®è—¥ç”¨åƒ¹å€¼ï¼Œç„¶è€Œé€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æª¢æ¸¬å’Œåˆ©ç”¨é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œç–¾ç—…çš„é é˜²ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°‹æ‰¾éé£Ÿç”¨æ¤ç‰©ä¸­çš„æ½›åœ¨è³‡æºæ–¹é¢ã€‚\n\nç ”ç©¶çš„ä¸»é¡Œæ˜¯å¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚é€™äº›åŒ–åˆç‰©åœ¨è¨±å¤šç ”ç©¶ä¸­é¡¯ç¤ºå‡ºæ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†ç”±æ–¼å®ƒå€‘ä¸»è¦å­˜åœ¨æ–¼ç‰¹å®šçš„è”¬èœä¸­ï¼Œé™åˆ¶äº†å…¶æ‡‰ç”¨ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶é—œæ³¨å¦‚ä½•å¾éé£Ÿç”¨æ¤ç‰©ä¸­æå–å’Œæª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä»¥æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€ééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚é€™ç¨®æ–¹æ³•çš„å„ªåŒ–æ¢ä»¶ä¸‹ï¼Œé¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œä½æª¢æ¸¬é™ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éé£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ä¹‹é–“ï¼Œæ¨™æº–åå·®å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–-è¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨çš„æ–¹æ³•åœ¨æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘èº«é‚Šçš„éé£Ÿç”¨æ¤ç‰©ä¹Ÿå¯èƒ½è—è‘—å¥åº·çš„ç§˜å¯†ï¼é€™é …æœ€æ–°ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å¯èƒ½æœ‰ç›Šå¥åº·çš„åŒ–åˆç‰©ï¼‰åŠå…¶å‰é«”ï¼Œè‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚é€™äº›åŒ–åˆç‰©ä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘çš„è”¬èœä¸­ï¼Œæ¯”å¦‚é’èŠ±æ¤°èœï¼Œä½†æˆ‘å€‘çš„ç§‘å­¸å®¶å€‘æƒ³çœ‹çœ‹èƒ½ä¸èƒ½åœ¨éé£Ÿç”¨æ¤ç‰©ä¸­æ‰¾åˆ°å®ƒå€‘ï¼\n\nç ”ç©¶åœ˜éšŠåˆæˆäº†ä¸€ç¨®ç‰¹æ®Šçš„ææ–™ï¼Œå¹«åŠ©ä»–å€‘æª¢æ¸¬éé£Ÿç”¨æ¤ç‰©ä¸­çš„é€™äº›åŒ–åˆç‰©ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™ç¨®æ–¹æ³•ä¸åƒ…æœ‰æ•ˆï¼Œé‚„èƒ½æº–ç¢ºåœ°æ‰¾å‡ºè‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ çš„å­˜åœ¨ï¼\n\nğŸ” ä¸»è¦çµæœåŒ…æ‹¬ï¼š\n1. åœ¨18ç¨®éé£Ÿç”¨æ¤ç‰©ä¸­æˆåŠŸæª¢æ¸¬åˆ°é€™äº›åŒ–åˆç‰©ã€‚\n2. æª¢æ¸¬çš„æº–ç¢ºæ€§é«˜ï¼Œå›æ”¶ç‡åœ¨89.1%åˆ°109.3%ä¹‹é–“ã€‚\n3. é€™é …æŠ€è¡“å¯èƒ½ç‚ºæœªä¾†å¥åº·ç”¢å“çš„é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼\n\né€™ä¸åƒ…æ˜¯ç§‘å­¸çš„é€²æ­¥ï¼Œä¹Ÿå¯èƒ½ç‚ºæˆ‘å€‘çš„å¥åº·å¸¶ä¾†æ›´å¤šçš„é¸æ“‡ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on the detection of health-beneficial compounds called glucoraphanin and rapeseed sulforaphane in non-edible plants. Use flat design style with soft colors on a white or light background. Include symbols representing broccoli or sulforaphane, simplified icons of experimental subjects like humans or cells, arrows or flow lines to indicate experimental steps, and a section labeled 'Main Results' showing key findings like recovery rates and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†è˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯ä¸€ç¨®æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶æˆåˆ†ä¾†å¢å¼·å‚³çµ±ç™‚æ³•çš„æ•ˆæœï¼Œä¸¦æ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚çµæœã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½åœ¨ç–¾ç—…é é˜²ä¸­æ‰®æ¼”æ›´ç‚ºé—œéµçš„è§’è‰²ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶å’Œæ¢ç´¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒï¼Œä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€™é …ç¶œè¿°æ•´åˆäº†ä¸åŒç ”ç©¶å±¤é¢çš„è³‡æ–™ï¼Œå¾æ¤ç‰©ä¸­è˜¿è””ç¡«ç´ çš„åˆæˆæ©Ÿåˆ¶åˆ°å…¶åœ¨äººé«”ä¸­çš„å…·é«”ä½œç”¨ï¼Œæä¾›äº†ä¸€å€‹å…¨æ–°çš„è¦–è§’ä¾†ç†è§£é€™ç¨®åŒ–åˆç‰©çš„æ½›åŠ›ã€‚",
    "para3": "ç ”ç©¶è€…æ¡ç”¨å¤šå±¤æ¬¡çš„åˆ†ææ–¹æ³•ï¼Œå¾åŸºå› å’Œè¡¨è§€éºå‚³å­¸çš„è§’åº¦æ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆï¼Œä¸¦è©•ä¼°å…¶åœ¨äººé«”ä¸­çš„æ•ˆæœã€‚ç ”ç©¶ä¸­è€ƒæ…®äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ å¯èƒ½å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ å»ºç«‹ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œä»¥ä¾¿æ›´æœ‰æ•ˆåœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ æ–¼ç™Œç—‡æ²»ç™‚ä¸­ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™‚æ³•æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸è›‹ç™½å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚é€™é …ç ”ç©¶ä¸åƒ…æä¾›äº†è˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ï¼Œé‚„å¼·èª¿äº†å…¶åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨æ½›åŠ›ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œæ‡‰ç”¨çš„å…·é«”æƒ…æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨ä¸åŒå€‹é«”ä¹‹é–“çš„å·®ç•°ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é€™é …ç ”ç©¶å¼·èª¿äº†è˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯ä¸€ç¨®æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„èƒ½å½±éŸ¿å¤šå€‹ç”Ÿç‰©å­¸é€”å¾‘ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶æˆåˆ†ä¾†å¢å¼·å‚³çµ±ç™‚æ³•çš„æ•ˆæœï¼Œä¸¦æ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚çµæœã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½åœ¨ç–¾ç—…é é˜²ä¸­æ‰®æ¼”æ›´ç‚ºé—œéµçš„è§’è‰²ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶å’Œæ¢ç´¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒï¼Œä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€™é …ç¶œè¿°æ•´åˆäº†ä¸åŒç ”ç©¶å±¤é¢çš„è³‡æ–™ï¼Œå¾æ¤ç‰©ä¸­è˜¿è””ç¡«ç´ çš„åˆæˆæ©Ÿåˆ¶åˆ°å…¶åœ¨äººé«”ä¸­çš„å…·é«”ä½œç”¨ï¼Œæä¾›äº†ä¸€å€‹å…¨æ–°çš„è¦–è§’ä¾†ç†è§£é€™ç¨®åŒ–åˆç‰©çš„æ½›åŠ›ã€‚\n\nç ”ç©¶è€…æ¡ç”¨å¤šå±¤æ¬¡çš„åˆ†ææ–¹æ³•ï¼Œå¾åŸºå› å’Œè¡¨è§€éºå‚³å­¸çš„è§’åº¦æ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆï¼Œä¸¦è©•ä¼°å…¶åœ¨äººé«”ä¸­çš„æ•ˆæœã€‚ç ”ç©¶ä¸­è€ƒæ…®äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ å¯èƒ½å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ å»ºç«‹ä¸€å€‹ç²¾æº–ç‡Ÿé¤Šçš„æ¡†æ¶ï¼Œä»¥ä¾¿æ›´æœ‰æ•ˆåœ°æ‡‰ç”¨è˜¿è””ç¡«ç´ æ–¼ç™Œç—‡æ²»ç™‚ä¸­ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™‚æ³•æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸è›‹ç™½å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚é€™é …ç ”ç©¶ä¸åƒ…æä¾›äº†è˜¿è””ç¡«ç´ çš„å…·é«”ä½œç”¨æ©Ÿåˆ¶ï¼Œé‚„å¼·èª¿äº†å…¶åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ‡‰ç”¨æ½›åŠ›ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœå’Œæ‡‰ç”¨çš„å…·é«”æƒ…æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨ä¸åŒå€‹é«”ä¹‹é–“çš„å·®ç•°ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œç«Ÿç„¶è—è‘—å°æŠ—ç™Œç—‡çš„ç§˜å¯†æ­¦å™¨ï¼é€™å°±æ˜¯ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯å€‹æŠ—æ°§åŒ–åŠ‘ï¼Œå®ƒé‚„èƒ½å½±éŸ¿æˆ‘å€‘èº«é«”è£¡çš„å¤šç¨®ç”Ÿç‰©å­¸éç¨‹ï¼Œå°å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºã€‚  \n  \né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒå’Œè…«ç˜¤çš„å…ç–«ç’°å¢ƒï¼Œä»¥åŠå®ƒåœ¨æˆ‘å€‘é«”å…§çš„æœ‰æ•ˆæ€§ã€‚ä»–å€‘å¾æ¤ç‰©çš„åˆæˆæ©Ÿåˆ¶åˆ°äººé«”çš„å…·é«”ä½œç”¨é€²è¡Œäº†æ·±å…¥åˆ†æï¼Œæä¾›äº†ä¸€å€‹å…¨æ–°çš„è¦–è§’ä¾†ç†è§£é€™ç¨®åŒ–åˆç‰©çš„æ½›åŠ›ã€‚  \n  \nç ”ç©¶è€…é‚„è€ƒæ…®äº†å½±éŸ¿è˜¿è””ç¡«ç´ æ•ˆæœçš„ä¸€äº›å› ç´ ï¼Œæ¯”å¦‚è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚é€éé€™äº›ç ”ç©¶ï¼Œä»–å€‘å¸Œæœ›èƒ½å»ºç«‹ä¸€å€‹æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†æ‡‰ç”¨è˜¿è””ç¡«ç´ æ–¼ç™Œç—‡æ²»ç™‚ä¸­ã€‚  \n  \nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±ç™‚æ³•æ–¹é¢æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚é›–ç„¶çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªé€™äº›æ•ˆæœã€‚  \n  \nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒå’Œå…ç–«ç’°å¢ƒ  \n2. ç ”ç©¶è€ƒé‡äº†è…¸é“å¾®ç”Ÿç‰©ç­‰å› ç´ çš„å½±éŸ¿  \n3. æœ‰æ½›åŠ›å¢å¼·å‚³çµ±ç™‚æ³•ï¼Œä½†éœ€æ›´å¤šç ”ç©¶ç¢ºèª",
    "image_prompt": "Create a flat design infographic explaining the experiment methods and main results of a study on sulforaphane, a compound found in cruciferous vegetables. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to show the steps of the experiment. Add a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é é˜²æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åŸºå› è¡¨é”ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½å°é™ä½èƒƒç™Œé¢¨éšªæœ‰å¹«åŠ©ã€‚é›–ç„¶é€™äº›çµæœé‚„éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªï¼Œä½†å®ƒå€‘ç‚ºæœªä¾†çš„é é˜²ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°èƒƒç™Œçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éå½±éŸ¿lncRNAèˆ‡å…¶ä»–åˆ†å­ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œä¾†æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚é€™å€‹å•é¡Œçš„è§£ç­”å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºé¡¯è‘—è¡¨é”è®ŠåŒ–çš„lncRNAã€‚æ¥è‘—ï¼Œåˆ©ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªè˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦ä¸”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚é€™äº›å¯¦é©—å¹«åŠ©ç ”ç©¶è€…ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒPSMB8-AS1åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨é”èˆ‡ç´°èƒçš„å¢æ®–å’Œé·ç§»æœ‰é—œï¼Œä¸”å…¶æŠ‘åˆ¶å¯ä»¥ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€šéèª¿ç¯€è½‰éŒ„å› å­YY1ä¾†æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”ï¼Œé€²è€Œå½±éŸ¿miR-888-5på’ŒSLC4A7çš„ä½œç”¨ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°èƒƒç™Œæœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ä¾†é©—è­‰å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é é˜²æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åŸºå› è¡¨é”ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½å°é™ä½èƒƒç™Œé¢¨éšªæœ‰å¹«åŠ©ã€‚é›–ç„¶é€™äº›çµæœé‚„éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªï¼Œä½†å®ƒå€‘ç‚ºæœªä¾†çš„é é˜²ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å°èƒƒç™Œçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éå½±éŸ¿lncRNAèˆ‡å…¶ä»–åˆ†å­ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œä¾†æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚é€™å€‹å•é¡Œçš„è§£ç­”å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥æ‰¾å‡ºé¡¯è‘—è¡¨é”è®ŠåŒ–çš„lncRNAã€‚æ¥è‘—ï¼Œåˆ©ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªè˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦ä¸”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚é€™äº›å¯¦é©—å¹«åŠ©ç ”ç©¶è€…ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒPSMB8-AS1åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨é”èˆ‡ç´°èƒçš„å¢æ®–å’Œé·ç§»æœ‰é—œï¼Œä¸”å…¶æŠ‘åˆ¶å¯ä»¥ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€šéèª¿ç¯€è½‰éŒ„å› å­YY1ä¾†æŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”ï¼Œé€²è€Œå½±éŸ¿miR-888-5på’ŒSLC4A7çš„ä½œç”¨ã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°èƒƒç™Œæœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ä¾†é©—è­‰å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ å°æˆ‘å€‘çš„å¥åº·æœ‰å¤šå¤§çš„å½±éŸ¿å—ï¼Ÿæœ€è¿‘çš„ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®å¤©ç„¶æˆåˆ†å¯èƒ½å°é é˜²èƒƒç™Œæœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„å¢é•·ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½èª¿ç¯€ä¸€äº›ç‰¹å®šçš„åŸºå› ï¼Œé€™äº›åŸºå› å’Œèƒƒç™Œçš„ç™¼å±•æœ‰é—œã€‚ä»–å€‘è§€å¯Ÿåˆ°ï¼Œè˜¿è””ç¡«ç´ æœƒå½±éŸ¿ä¸€ç¨®å«åšé•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„åˆ†å­ï¼Œé€™å¯èƒ½å¹«åŠ©æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œäº†æ·±å…¥åˆ†æï¼Œä¸¦ç™¼ç¾äº†ä¸€äº›é‡è¦çš„è®ŠåŒ–ï¼Œç‰¹åˆ¥æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„åˆ†å­ï¼Œå®ƒèˆ‡ç™Œç´°èƒçš„å¢æ®–å’Œæ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚é€™äº›çµæœè®“ç§‘å­¸å®¶å€‘æ›´äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nğŸ”ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€åŸºå› ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚\n2. ç ”ç©¶ç™¼ç¾PSMB8-AS1èˆ‡èƒƒç™Œç´°èƒçš„å¢æ®–æœ‰é—œï¼ŒæŠ‘åˆ¶å®ƒå¯èƒ½æœƒä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚\n3. é›–ç„¶çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane from broccoli. Use a flat design style with a light background and soft colors. Include simple icons representing broccoli and sulforaphane, as well as simplified representations of experimental subjects like cells. Incorporate arrows or flow lines to indicate the steps of the experiment. Add a section that highlights the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "journal": "RSC medicinal chemistry",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ‰€å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œé ˜åŸŸï¼Œç ”ç©¶äººå“¡æ­£åœ¨å°‹æ‰¾æ–°å‹çš„è—¥ç‰©ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™ä¸åƒ…èƒ½å¹«åŠ©æ‚£è€…æ”¹å–„å¥åº·ç‹€æ³ï¼Œä¹Ÿå¯èƒ½é™ä½ç™Œç—‡çš„ç™¼ç—…ç‡ã€‚é€éå¤©ç„¶ç”¢å“çš„ç‰¹æ€§ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œï¼ˆnasopharyngeal carcinoma, NPCï¼‰ã€‚ç ”ç©¶è€…å€‘é—œæ³¨å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢ç‰©ä¸­çš„æœ‰æ•ˆæˆåˆ†ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œä¾†è¨­è¨ˆå‡ºæ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä»¥æé«˜æŠ—ç™Œæ•ˆæœã€‚é€™ä¸åƒ…æ˜¯å°ç¾æœ‰æ²»ç™‚æ–¹æ³•çš„è£œå……ï¼Œä¹Ÿå¯èƒ½ç‚ºç™Œç—‡æ‚£è€…å¸¶ä¾†æ–°çš„å¸Œæœ›ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶åœ˜éšŠè¨­è¨ˆäº†ä¸€ç³»åˆ—ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åˆ†å­æ··åˆç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤è©•ä¼°ã€‚ä»–å€‘é¸æ“‡äº†é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¾†æ¸¬è©¦é€™äº›æ–°åŒ–åˆç‰©çš„æ•ˆæœã€‚é€éåˆæˆç­–ç•¥ï¼Œç ”ç©¶è€…å€‘æˆåŠŸåœ°è­˜åˆ¥å‡ºä¸€ç¨®åç‚ºCTNPC8çš„åŒ–åˆç‰©ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™äº›å¯¦é©—æä¾›äº†å°æ–¼æ–°è—¥ç‰©é–‹ç™¼çš„é‡è¦æ•¸æ“šã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶åŸå§‹æˆåˆ†å’Œé †é‰‘ã€‚ç ”ç©¶ç™¼ç¾ï¼ŒCTNPC8èƒ½å¤ é€éèª¿ç¯€æ´»æ€§æ°§ï¼ˆROSï¼‰çš„ç”Ÿæˆä¾†èª˜å°ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒåœæ»¯åœ¨G2/MæœŸã€‚æ­¤å¤–ï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ‰€å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œé ˜åŸŸï¼Œç ”ç©¶äººå“¡æ­£åœ¨å°‹æ‰¾æ–°å‹çš„è—¥ç‰©ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™ä¸åƒ…èƒ½å¹«åŠ©æ‚£è€…æ”¹å–„å¥åº·ç‹€æ³ï¼Œä¹Ÿå¯èƒ½é™ä½ç™Œç—‡çš„ç™¼ç—…ç‡ã€‚é€éå¤©ç„¶ç”¢å“çš„ç‰¹æ€§ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œï¼ˆnasopharyngeal carcinoma, NPCï¼‰ã€‚ç ”ç©¶è€…å€‘é—œæ³¨å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢ç‰©ä¸­çš„æœ‰æ•ˆæˆåˆ†ï¼Œåƒæ˜¯è˜¿è””ç¡«ç´ ï¼Œä¾†è¨­è¨ˆå‡ºæ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä»¥æé«˜æŠ—ç™Œæ•ˆæœã€‚é€™ä¸åƒ…æ˜¯å°ç¾æœ‰æ²»ç™‚æ–¹æ³•çš„è£œå……ï¼Œä¹Ÿå¯èƒ½ç‚ºç™Œç—‡æ‚£è€…å¸¶ä¾†æ–°çš„å¸Œæœ›ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶åœ˜éšŠè¨­è¨ˆäº†ä¸€ç³»åˆ—ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åˆ†å­æ··åˆç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤è©•ä¼°ã€‚ä»–å€‘é¸æ“‡äº†é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¾†æ¸¬è©¦é€™äº›æ–°åŒ–åˆç‰©çš„æ•ˆæœã€‚é€éåˆæˆç­–ç•¥ï¼Œç ”ç©¶è€…å€‘æˆåŠŸåœ°è­˜åˆ¥å‡ºä¸€ç¨®åç‚ºCTNPC8çš„åŒ–åˆç‰©ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™äº›å¯¦é©—æä¾›äº†å°æ–¼æ–°è—¥ç‰©é–‹ç™¼çš„é‡è¦æ•¸æ“šã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶åŸå§‹æˆåˆ†å’Œé †é‰‘ã€‚ç ”ç©¶ç™¼ç¾ï¼ŒCTNPC8èƒ½å¤ é€éèª¿ç¯€æ´»æ€§æ°§ï¼ˆROSï¼‰çš„ç”Ÿæˆä¾†èª˜å°ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒåœæ»¯åœ¨G2/MæœŸã€‚æ­¤å¤–ï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—è…«ç˜¤åŒ–åˆç‰©ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠRSC medicinal chemistryã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿè£¡ç«Ÿç„¶éš±è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼\n\næœ€è¿‘ä¸€é …æœ‰è¶£çš„ç ”ç©¶èšç„¦åœ¨å¤©ç„¶ç”¢å“ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼‰å¦‚ä½•å¹«åŠ©å°æŠ—é¼»å’½ç™Œã€‚ç ”ç©¶äººå“¡å¸Œæœ›é€éé€™äº›å¤©ç„¶æˆåˆ†ï¼Œé–‹ç™¼å‡ºæ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œå¹«åŠ©æ‚£è€…æ”¹å–„å¥åº·ï¼Œç”šè‡³é™ä½ç™Œç—‡çš„é¢¨éšªã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åŒ–åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤è£¡æ¸¬è©¦å®ƒå€‘å°é¼»å’½ç™Œç´°èƒçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œåç‚ºCTNPC8çš„åŒ–åˆç‰©å±•ç¾äº†å¼·å¤§çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³æ¯”åŸå§‹æˆåˆ†é‚„è¦æœ‰æ•ˆï¼\n\né€™äº›åŒ–åˆç‰©èƒ½å¤ ä¿ƒä½¿ç™Œç´°èƒå‡‹äº¡ï¼Œä¸¦ä¸”å½±éŸ¿ç´°èƒçš„ç”Ÿé•·é€±æœŸï¼Œè®“ç™Œç´°èƒç„¡æ³•æ­£å¸¸ç¹æ®–ã€‚é›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªCTNPC8çš„ç™‚æ•ˆã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æ˜¯æŠ—ç™Œæ–°å¸Œæœ›ï¼\n2. CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a simple infographic that explains the experimental methods and main results of a study on a compound called CTNPC8 derived from natural products like sulforaphane. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells, and arrows or flow lines indicating the experimental steps. Include a section clearly labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ç”±æ•—è¡€ç—‡å¼•èµ·çš„ä¸€ç¨®è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™å¯èƒ½ä½¿å…¶æˆç‚ºä¸€ç¨®æ½›åœ¨çš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ¸›è¼•ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„é å¾Œã€‚é€™å°æ–¼å°‹æ‰¾æ–°ç™‚æ³•ä»¥å°æŠ—æ€¥æ€§è‚æå‚·çš„ç ”ç©¶å…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯åœ¨æ•—è¡€ç—‡æ‚£è€…ä¸­ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­çš„è—¥ç†ä½œç”¨å’Œæ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•LPSå¼•èµ·çš„è‚æå‚·ï¼Œä¸¦ä¸”å®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„ç›´æ¥æ•ˆæœï¼Œé‚„æ·±å…¥æ¢è¨äº†å…¶åœ¨ç´°èƒå±¤é¢ä¸Šçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°ç™¼ç‚åæ‡‰å’Œç´°èƒæ­»äº¡çš„èª¿æ§ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†çµ„ç¹”æŸ“è‰²å’ŒåŸºå› æ¸¬åºç­‰æ–¹æ³•ä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·ç¨‹åº¦å’Œç™¼ç‚åæ‡‰ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶å°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ¸›å°‘è‚è‡Ÿä¸­çš„ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦ä¸‹èª¿å¤šç¨®ç™¼ç‚ç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ é€šéæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSå¼•èµ·çš„è‚æå‚·å’Œç™¼ç‚ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ç”±æ•—è¡€ç—‡å¼•èµ·çš„ä¸€ç¨®è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™å¯èƒ½ä½¿å…¶æˆç‚ºä¸€ç¨®æ½›åœ¨çš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ¸›è¼•ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‚æå‚·ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„é å¾Œã€‚é€™å°æ–¼å°‹æ‰¾æ–°ç™‚æ³•ä»¥å°æŠ—æ€¥æ€§è‚æå‚·çš„ç ”ç©¶å…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯åœ¨æ•—è¡€ç—‡æ‚£è€…ä¸­ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­çš„è—¥ç†ä½œç”¨å’Œæ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•LPSå¼•èµ·çš„è‚æå‚·ï¼Œä¸¦ä¸”å®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„ç›´æ¥æ•ˆæœï¼Œé‚„æ·±å…¥æ¢è¨äº†å…¶åœ¨ç´°èƒå±¤é¢ä¸Šçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°ç™¼ç‚åæ‡‰å’Œç´°èƒæ­»äº¡çš„èª¿æ§ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†çµ„ç¹”æŸ“è‰²å’ŒåŸºå› æ¸¬åºç­‰æ–¹æ³•ä¾†è©•ä¼°è‚è‡Ÿçš„æå‚·ç¨‹åº¦å’Œç™¼ç‚åæ‡‰ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³å’Œè‚è‡Ÿçš„ç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶å°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ¸›å°‘è‚è‡Ÿä¸­çš„ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦ä¸‹èª¿å¤šç¨®ç™¼ç‚ç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ é€šéæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSå¼•èµ·çš„è‚æå‚·å’Œç™¼ç‚ã€‚é€™äº›çµæœç‚ºè˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·æ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›æˆåˆ†å¯èƒ½å°è‚è‡Ÿå¥åº·æœ‰ç‰¹åˆ¥çš„å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®åœ¨è˜¿è””å’Œé’èŠ±æ¤°èœä¸­æ‰¾åˆ°çš„å¤©ç„¶æˆåˆ†ï¼‰å¯èƒ½å°æ€¥æ€§è‚æå‚·æœ‰ä¿è­·ä½œç”¨ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©æ¸›è¼•ç”±ä¸€ç¨®å«è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„è‚æå‚·ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨å°é¼ æ¨¡å‹ï¼Œå°‡å°é¼ åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆä¸åŒçš„è™•ç†ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„è‚è‡Ÿåæ‡‰ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½é™ä½è‚è‡Ÿæå‚·çš„ç¨‹åº¦ï¼Œé‚„èƒ½æ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œé€™å°æ–¼æ€¥æ€§è‚æå‚·çš„æ²»ç™‚å¯èƒ½æ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\nâœ¨ é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½é™ä½è‚è‡Ÿæå‚·åŠç™¼ç‚åæ‡‰ã€‚\n3. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚æ€¥æ€§è‚æå‚·çš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of a study on the protective effects of sulforaphane from broccoli and radish on acute liver injury. Include simplified icons representing sulforaphane, experimental subjects (like mice or cells), and arrows or flow lines to indicate the steps of the experiment. Add a section labeled 'Main Findings' highlighting the protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "journal": "GeroScience",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•é©æ‡‰èƒ½åŠ›ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œäººé«”å°æ–¼æ€¥æ€§é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é‹å‹•å¾Œçš„å¥åº·ç›Šè™•å¯èƒ½ä¸å¦‚å¹´è¼•äººæ˜é¡¯ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•ï¼Œå°æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³å’Œç”Ÿæ´»è³ªé‡æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„æ½›åŠ›ï¼Œå¯èƒ½ç‚ºå¹´é•·è€…æä¾›æ›´å¥½çš„å¥åº·ä¿ƒé€²æ–¹æ¡ˆã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡æ€¥æ€§é‹å‹•çµåˆå¾Œï¼Œå°å¹´é•·è€…çš„NRF2æ´»åŒ–å’Œä¿¡è™Ÿå‚³éçš„å½±éŸ¿ã€‚NRF2æ˜¯ä¸€ç¨®é‡è¦çš„æŠ—æ°§åŒ–å› å­ï¼Œèƒ½å¤ å¹«åŠ©ç´°èƒæŠµæŠ—æ°§åŒ–å£“åŠ›ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …å¯¦é©—ï¼Œäº†è§£åœ¨å¹´é•·è€…ä¸­ï¼Œé‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„è¯åˆä½¿ç”¨æ˜¯å¦èƒ½å¤ æ¯”å–®ç¨ä½¿ç”¨ä»»ä½•ä¸€ç¨®æ–¹æ³•æ›´æœ‰æ•ˆåœ°ä¿ƒé€²NRF2çš„æ´»åŒ–ï¼Œé€²è€Œæ”¹å–„å¥åº·ç‹€æ³ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„è…³è¸è»Šé‹å‹•ã€‚é‹å‹•å‰å¾Œï¼Œç ”ç©¶åœ˜éšŠæŠ½å–è¡€æ¶²ä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒèˆ‡æˆ–ä¸èˆ‡è˜¿è””ç¡«ç´ ï¼ˆ5 ÂµMï¼‰ä¸€èµ·åŸ¹é¤Šï¼Œå½¢æˆå››ç¨®ä¸åŒçš„è™•ç†æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†é€™äº›ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»åŒ–ç¨‹åº¦åŠç›¸é—œåŸºå› çš„è¡¨é”ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰ç›¸æ¯”å°ç…§çµ„å‡æé«˜äº†NRF2çš„æ´»åŒ–ç¨‹åº¦ï¼Œè€Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„åæ‡‰é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ã€‚å…·é«”ä¾†èªªï¼Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„NRF2æ´»åŒ–ç¨‹åº¦æ˜¯å–®ç¨é‹å‹•çš„2.1å€ï¼Œè€Œå–®ç¨è˜¿è””ç¡«ç´ å‰‡æ˜¯1.5å€ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€é¡¯è‘—ä¸Šèª¿äº†å››å€‹åŸºå› çš„è¡¨é”ï¼Œä½†é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„åŸºå› è¡¨é”å¢å¹…ä¸¦æœªé¡¯è‘—é«˜æ–¼å–®ç¨çš„é‹å‹•ï¼Œé€™å¯èƒ½æš—ç¤ºäº†è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šçš„æŸç¨®ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶çµæœæœªé¡¯ç¤ºæ€§åˆ¥å°åæ‡‰æœ‰é¡¯è‘—å½±éŸ¿ï¼Œé€™è¡¨æ˜é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„çµåˆå¯èƒ½å°å¹´é•·è€…çš„NRF2/AREç´…æ°§ä¿¡è™Ÿå‚³éæœ‰å¢å¼·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•é©æ‡‰èƒ½åŠ›ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œäººé«”å°æ–¼æ€¥æ€§é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é‹å‹•å¾Œçš„å¥åº·ç›Šè™•å¯èƒ½ä¸å¦‚å¹´è¼•äººæ˜é¡¯ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•ï¼Œå°æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³å’Œç”Ÿæ´»è³ªé‡æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„æ½›åŠ›ï¼Œå¯èƒ½ç‚ºå¹´é•·è€…æä¾›æ›´å¥½çš„å¥åº·ä¿ƒé€²æ–¹æ¡ˆã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡æ€¥æ€§é‹å‹•çµåˆå¾Œï¼Œå°å¹´é•·è€…çš„NRF2æ´»åŒ–å’Œä¿¡è™Ÿå‚³éçš„å½±éŸ¿ã€‚NRF2æ˜¯ä¸€ç¨®é‡è¦çš„æŠ—æ°§åŒ–å› å­ï¼Œèƒ½å¤ å¹«åŠ©ç´°èƒæŠµæŠ—æ°§åŒ–å£“åŠ›ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …å¯¦é©—ï¼Œäº†è§£åœ¨å¹´é•·è€…ä¸­ï¼Œé‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„è¯åˆä½¿ç”¨æ˜¯å¦èƒ½å¤ æ¯”å–®ç¨ä½¿ç”¨ä»»ä½•ä¸€ç¨®æ–¹æ³•æ›´æœ‰æ•ˆåœ°ä¿ƒé€²NRF2çš„æ´»åŒ–ï¼Œé€²è€Œæ”¹å–„å¥åº·ç‹€æ³ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„è…³è¸è»Šé‹å‹•ã€‚é‹å‹•å‰å¾Œï¼Œç ”ç©¶åœ˜éšŠæŠ½å–è¡€æ¶²ä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒèˆ‡æˆ–ä¸èˆ‡è˜¿è””ç¡«ç´ ï¼ˆ5 ÂµMï¼‰ä¸€èµ·åŸ¹é¤Šï¼Œå½¢æˆå››ç¨®ä¸åŒçš„è™•ç†æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†é€™äº›ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»åŒ–ç¨‹åº¦åŠç›¸é—œåŸºå› çš„è¡¨é”ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰ç›¸æ¯”å°ç…§çµ„å‡æé«˜äº†NRF2çš„æ´»åŒ–ç¨‹åº¦ï¼Œè€Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„åæ‡‰é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ã€‚å…·é«”ä¾†èªªï¼Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„NRF2æ´»åŒ–ç¨‹åº¦æ˜¯å–®ç¨é‹å‹•çš„2.1å€ï¼Œè€Œå–®ç¨è˜¿è””ç¡«ç´ å‰‡æ˜¯1.5å€ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çš„åˆºæ¿€é¡¯è‘—ä¸Šèª¿äº†å››å€‹åŸºå› çš„è¡¨é”ï¼Œä½†é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„åŸºå› è¡¨é”å¢å¹…ä¸¦æœªé¡¯è‘—é«˜æ–¼å–®ç¨çš„é‹å‹•ï¼Œé€™å¯èƒ½æš—ç¤ºäº†è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šçš„æŸç¨®ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶çµæœæœªé¡¯ç¤ºæ€§åˆ¥å°åæ‡‰æœ‰é¡¯è‘—å½±éŸ¿ï¼Œé€™è¡¨æ˜é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„çµåˆå¯èƒ½å°å¹´é•·è€…çš„NRF2/AREç´…æ°§ä¿¡è™Ÿå‚³éæœ‰å¢å¼·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠGeroScienceã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç§˜å¯†æˆåˆ†å¯èƒ½å°å¹´é•·è€…çš„å¥åº·æœ‰å¤§å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å’Œé‹å‹•å°å¹´é•·è€…çš„å½±éŸ¿ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œäººé«”å°é‹å‹•çš„åæ‡‰å¯èƒ½è®Šå¾—ä¸å¦‚å¹´è¼•æ™‚é‚£éº¼å¼·çƒˆï¼Œå› æ­¤ï¼Œæ‰¾åˆ°èƒ½å¢å¼·é‹å‹•æ•ˆæœçš„æ–¹æ³•è®Šå¾—ç›¸ç•¶é‡è¦ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£ï¼Œçµåˆé‹å‹•å’Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ›´æœ‰æ•ˆåœ°æé«˜ä¸€ç¨®å«åšNRF2çš„æŠ—æ°§åŒ–å› å­çš„æ´»åŒ–ï¼Œé€™å°å¥åº·æœ‰å¾ˆå¤§å¹«åŠ©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œ25ä½å¹´é•·è€…åƒåŠ äº†30åˆ†é˜çš„è…³è¸è»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾Œé€²è¡Œäº†è¡€æ¶²æª¢æ¸¬ã€‚çµæœç™¼ç¾ï¼Œç„¡è«–æ˜¯å–®ç¨é‹å‹•é‚„æ˜¯å–®ç¨è˜¿è””ç¡«ç´ ï¼Œéƒ½èƒ½æé«˜NRF2çš„æ´»åŒ–ç¨‹åº¦ï¼Œä½†ç•¶å…©è€…çµåˆæ™‚ï¼Œæ•ˆæœæ›´ä½³ï¼é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„NRF2æ´»åŒ–ç¨‹åº¦æ˜¯å–®ç¨é‹å‹•çš„2.1å€ï¼Œé€™æ„å‘³è‘—é€™ç¨®çµ„åˆå¯èƒ½å°å¹´é•·è€…çš„å¥åº·æœ‰æ›´å¥½çš„ä¿ƒé€²æ•ˆæœã€‚\n\nğŸ”‘ é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé‹å‹•çµåˆèƒ½é¡¯è‘—æé«˜æŠ—æ°§åŒ–å› å­NRF2çš„æ´»åŒ–ã€‚\n2. å¹´é•·è€…çš„é‹å‹•æ•ˆæœå¯èƒ½å› å¹´é½¡è€Œç•°ï¼Œå°‹æ‰¾è¼”åŠ©æ–¹æ³•å¾ˆé‡è¦ã€‚\n3. é€™é …ç ”ç©¶ç‚ºå¹´é•·è€…çš„å¥åº·ä¿ƒé€²æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane (SFN) and exercise in older adults. Include symbols for broccoli or sulforaphane, simplified representations of human subjects or cells, arrows or flow lines to indicate experimental steps, and a section highlighting the main results such as NRF2 activation levels and protective effects.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  },
  {
    "id": "40763479",
    "title_en": "Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy.",
    "pub_date": "2025 Oct",
    "journal": "International immunopharmacology",
    "abstract_en": "Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸èˆ‡æ…¢æ€§ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‚Œè…±çš„ç™¼ç‚åæ‡‰ï¼Œé€²è€Œæ”¹å–„ç—…ç—‡ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨æ²»ç™‚è‚Œè…±ç—…æ™‚ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†é”åˆ°æ›´å¥½çš„æ•ˆæœï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éèª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ä¾†æ”¹å–„è‚Œè…±ç—…çš„ç—…ç†ç‹€æ…‹ã€‚å·¨å™¬ç´°èƒæ˜¯å…ç–«ç³»çµ±ä¸­çš„é‡è¦ç´°èƒï¼Œè² è²¬èª¿ç¯€ç™¼ç‚åæ‡‰ã€‚ç ”ç©¶å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹è®Šé€™äº›ç´°èƒçš„è¡Œç‚ºï¼Œä¸¦é€²ä¸€æ­¥å½±éŸ¿è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ–½ç”¨è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…ä¹Ÿåœ¨é«”å¤–é€²è¡Œäº†å¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢è¨å…¶èª¿ç¯€æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œé‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ä¾†é€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„æ²»ç™‚æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç™¼ç‚åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªæª¢æ¸¬çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™æœ‰åŠ©æ–¼ç‚ç—‡çš„ç·©è§£ã€‚æ­¤å¤–ï¼Œé€™ä¸€å…ç–«èª¿ç¯€æ•ˆæœåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­ä¹Ÿå¾—åˆ°äº†é©—è­‰ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸èˆ‡æ…¢æ€§ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™æœ‰é—œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‚Œè…±çš„ç™¼ç‚åæ‡‰ï¼Œé€²è€Œæ”¹å–„ç—…ç—‡ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨æ²»ç™‚è‚Œè…±ç—…æ™‚ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†é”åˆ°æ›´å¥½çš„æ•ˆæœï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éèª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ä¾†æ”¹å–„è‚Œè…±ç—…çš„ç—…ç†ç‹€æ…‹ã€‚å·¨å™¬ç´°èƒæ˜¯å…ç–«ç³»çµ±ä¸­çš„é‡è¦ç´°èƒï¼Œè² è²¬èª¿ç¯€ç™¼ç‚åæ‡‰ã€‚ç ”ç©¶å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹è®Šé€™äº›ç´°èƒçš„è¡Œç‚ºï¼Œä¸¦é€²ä¸€æ­¥å½±éŸ¿è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ–½ç”¨è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…ä¹Ÿåœ¨é«”å¤–é€²è¡Œäº†å¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢è¨å…¶èª¿ç¯€æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œé‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ä¾†é€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„æ²»ç™‚æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç™¼ç‚åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªæª¢æ¸¬çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™æœ‰åŠ©æ–¼ç‚ç—‡çš„ç·©è§£ã€‚æ­¤å¤–ï¼Œé€™ä¸€å…ç–«èª¿ç¯€æ•ˆæœåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­ä¹Ÿå¾—åˆ°äº†é©—è­‰ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°é‹å‹•å—å‚·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†æˆ–è¨±èƒ½å¹«åŠ©æ”¹å–„è‚Œè…±ç—…ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œæœƒè®“äººæ„Ÿåˆ°æ…¢æ€§ç–¼ç—›ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦é€éèª¿æ•´æˆ‘å€‘èº«é«”ä¸­çš„å…ç–«ç´°èƒï¼Œä¾†æ¸›å°‘è‚Œè…±çš„ç™¼ç‚åæ‡‰ã€‚ \n\nä»–å€‘é€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œä½¿ç”¨äº†æ¨¡æ“¬è‚Œè…±ç—…çš„è€é¼ æ¨¡å‹ï¼Œä¸¦åœ¨å¯¦é©—å®¤ä¸­è§€å¯Ÿè˜¿è””ç¡«ç´ å°å…ç–«ç´°èƒçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆå¹«åŠ©èª¿æ•´å…ç–«ç´°èƒçš„è¡Œç‚ºï¼Œæ¸›å°‘ç™¼ç‚ï¼Œä¸¦æ”¹å–„è‚Œè…±çš„å¥åº·ã€‚ \n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„è‚Œè…±ç—…æ²»ç™‚æœ‰äº†æ–°çš„å¸Œæœ›ï¼Œç‰¹åˆ¥æ˜¯å°é‹å‹•å“¡å’Œéœ€è¦ä¿æŒæ´»å‹•çš„äººä¾†èªªï¼ \n\né‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‚Œè…±ç—…çš„ç—‡ç‹€ã€‚\n2. å®ƒèƒ½èª¿æ•´å…ç–«ç´°èƒï¼Œæ¸›å°‘ç™¼ç‚åæ‡‰ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‡ªç„¶ç™‚æ³•æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on the effects of sulforaphane on tendon health. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to indicate the experimental steps. Add a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œè…±ç—… Tendinopathy",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40763479/"
  },
  {
    "id": "41060333",
    "title_en": "Sulforaphane from broccoli, an epigenetic modulator in cancer cells.",
    "pub_date": "2025 Oct",
    "journal": "Discover oncology",
    "abstract_en": "The consumption of cruciferous vegetables offers several health benefits due to some of their compounds. Sulforaphane (SFN), a compound found in cabbage and broccoli, has received special attention in recent years due to its anticancer activities. The main objective of this systematic review is to examine the epigenetic and genetic effects of SFN on cancers (in vitro and in vivo) which contribute to its anticancer activities. We only analyzed studies that combined its epigenetic effects and anticancer activities due to the multitude of studies on SFN over the past few years. We found that SFN is able to regulate epigenetic mechanisms and promote the prevention and treatment of several cancers. Definitely, it prevents tumor growth and acts as a histone deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, and a microRNA regulator in several cancers. These epigenetic regulations lead indirectly to a hyperregulation or deregulation of the expression of genes involved in carcinogenesis. SFN hasn't any major epigenetic effect on normal cells. This review revealed that the anticancer activities attributable to SFN are largely related to its ability to modulate cancer cell epigenome. These capabilities to modulate the epigenome make SFN a promising anticancer agent with significant therapeutic potential.",
    "para1": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦æ­¸åŠŸæ–¼å…¶ä¸­çš„ä¸€äº›åŒ–åˆç‰©ã€‚æœ€è¿‘ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éå¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç™Œç—‡ï¼Œä¸¦æ”¹å–„æ•´é«”å¥åº·ç‹€æ³ã€‚é›–ç„¶é€™äº›ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ï¼Œä½†æˆ‘å€‘ä»éœ€è¬¹æ…çœ‹å¾…ï¼Œå› ç‚ºé€™ä¸¦ä¸ä»£è¡¨å®ƒèƒ½å¤ å®Œå…¨æ²»ç™’ç™Œç—‡æˆ–å–ä»£å‚³çµ±æ²»ç™‚ã€‚",
    "para2": "é€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œä¸¦ä¸”é€™äº›å½±éŸ¿æ˜¯å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨çš„ã€‚ç”±æ–¼éå»å¹¾å¹´å°è˜¿è””ç¡«ç´ çš„ç ”ç©¶æ•¸é‡çœ¾å¤šï¼Œé€™é …å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»å‹•çš„çµåˆä¸Šã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶å°è±¡ä¸»è¦æ˜¯ç™Œç´°èƒï¼Œä¸¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬å°è˜¿è””ç¡«ç´ çš„ä½œç”¨é€²è¡Œç¶œåˆè©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨èª¿ç¯€åŸºå› è¡¨é”æ–¹é¢çš„èƒ½åŠ›ï¼Œä»¥åŠå®ƒåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯ä»¥æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNAç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘åŠå¾®å°RNAèª¿ç¯€å› å­ã€‚é€™äº›è¡¨è§€éºå‚³èª¿ç¯€ä½œç”¨é–“æ¥å½±éŸ¿äº†èˆ‡ç™Œç—‡ç™¼ç”Ÿç›¸é—œçš„åŸºå› è¡¨é”ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒä¸¦æ²’æœ‰é¡¯è‘—çš„è¡¨è§€éºå‚³å½±éŸ¿ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ä¸»è¦ä¾†è‡ªæ–¼å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›ã€‚",
    "explanation_zh": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦æ­¸åŠŸæ–¼å…¶ä¸­çš„ä¸€äº›åŒ–åˆç‰©ã€‚æœ€è¿‘ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éå¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç™Œç—‡ï¼Œä¸¦æ”¹å–„æ•´é«”å¥åº·ç‹€æ³ã€‚é›–ç„¶é€™äº›ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ï¼Œä½†æˆ‘å€‘ä»éœ€è¬¹æ…çœ‹å¾…ï¼Œå› ç‚ºé€™ä¸¦ä¸ä»£è¡¨å®ƒèƒ½å¤ å®Œå…¨æ²»ç™’ç™Œç—‡æˆ–å–ä»£å‚³çµ±æ²»ç™‚ã€‚\n\né€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ï¼Œä¸¦ä¸”é€™äº›å½±éŸ¿æ˜¯å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨çš„ã€‚ç”±æ–¼éå»å¹¾å¹´å°è˜¿è””ç¡«ç´ çš„ç ”ç©¶æ•¸é‡çœ¾å¤šï¼Œé€™é …å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»å‹•çš„çµåˆä¸Šã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶å°è±¡ä¸»è¦æ˜¯ç™Œç´°èƒï¼Œä¸¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬å°è˜¿è””ç¡«ç´ çš„ä½œç”¨é€²è¡Œç¶œåˆè©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨èª¿ç¯€åŸºå› è¡¨é”æ–¹é¢çš„èƒ½åŠ›ï¼Œä»¥åŠå®ƒåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å¯ä»¥æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNAç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘åŠå¾®å°RNAèª¿ç¯€å› å­ã€‚é€™äº›è¡¨è§€éºå‚³èª¿ç¯€ä½œç”¨é–“æ¥å½±éŸ¿äº†èˆ‡ç™Œç—‡ç™¼ç”Ÿç›¸é—œçš„åŸºå› è¡¨é”ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒä¸¦æ²’æœ‰é¡¯è‘—çš„è¡¨è§€éºå‚³å½±éŸ¿ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„æ½›åŠ›ä¸»è¦ä¾†è‡ªæ–¼å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ æœ‰æ²’æœ‰æƒ³éï¼Œåƒé’èŠ±æ¤°èœç«Ÿç„¶å¯èƒ½å¹«åŠ©é é˜²ç™Œç—‡å‘¢ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­çš„åŒ–åˆç‰©ï¼‰æˆç‚ºç„¦é»ï¼ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦‚ä½•é€éèª¿æ•´åŸºå› è¡¨é”ä¾†å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ã€‚é€™é …ç³»çµ±æ€§å›é¡§åˆ†æäº†è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨ç™Œç´°èƒä¸­çš„ä½œç”¨ã€‚ ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½å¤ æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œé‚„èƒ½å½±éŸ¿èˆ‡ç™Œç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œé€™äº›æ•ˆæœå°æ­£å¸¸ç´°èƒæ²’æœ‰é¡¯è‘—å½±éŸ¿ï¼\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½èª¿ç¯€ç™Œç´°èƒçš„åŸºå› è¡¨é”ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚\n2. å®ƒå¯ä»¥æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦å½±éŸ¿å¤šç¨®è¡¨è§€éºå‚³æ©Ÿåˆ¶ã€‚\n3. åƒæ›´å¤šé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œæˆ–è¨±èƒ½æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ï¼\n\nä¸éï¼Œè¨˜å¾—é€™äº›ç ”ç©¶çµæœä¸¦ä¸ä»£è¡¨è˜¿è””ç¡«ç´ å¯ä»¥æ²»ç™’ç™Œç—‡ï¼Œé‚„æ˜¯è¦ä¾è³´å°ˆæ¥­çš„é†«ç™‚æ²»ç™‚å–”ï¼",
    "image_prompt": "Create an infographic that visually explains the experimental methods and main findings of a study on sulforaphane. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like humans, animals, or cells, and arrows or flow lines indicating the experimental steps. Add a section highlighting the main results, such as cancer protection effects or changes observed. Use a flat design style with a white or light-colored background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41060333/"
  },
  {
    "id": "40553560",
    "title_en": "Antibacterial effects of sulforaphane - AÂ phytonutrient derived from broccoli asÂ promising candidate in the combat ofÂ bacterial infections.",
    "pub_date": "2025 Oct",
    "journal": "European journal of microbiology & immunology",
    "abstract_en": "Bacterial pathogens, particularly antibiotic-resistant strains may constitute major challenges for the successful treatment of infected patients. Therefore, novel antibiotics or alternative, antibiotics-independent compounds with antimicrobial properties such as phytonutrients are needed. Our systematic literature review summarizes current knowledge on antibacterial effects of sulforaphane (SFN) in vitro and in vivo, including human studies. The isothiocyanate SFN is abundant in plants from the BrassicaceaeÂ family including broccoli. The 28 reports reviewed herein revealed that SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.)Â enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis. In conclusion, given its antibacterial, immune-modulatory, and disease-alleviating effects, SFN constitutesÂ a promising alternative antibiotic-independent candidate for the treatment of bacterial infections, warranting further consideration in clinical trials.",
    "para1": "åœ¨ç•¶ä»Šçš„é†«ç™‚ç’°å¢ƒä¸­ï¼ŒæŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å‡ºç¾ä½¿å¾—æ²»ç™‚æ„ŸæŸ“è®Šå¾—æ›´åŠ å›°é›£ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–å…·æœ‰æŠ—èŒç‰¹æ€§çš„åŒ–åˆç‰©è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ„ŸæŸ“æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç”Ÿç´ ç„¡æ³•å¥æ•ˆçš„æƒ…æ³ä¸‹ï¼Œé€™äº›å¤©ç„¶æ¤ç‰©æˆåˆ†å¯èƒ½æˆç‚ºæœ‰æ•ˆçš„æ›¿ä»£æ–¹æ¡ˆï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°é é˜²å’Œæ²»ç™‚ç´°èŒæ„ŸæŸ“ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨æŠ—èŒæ–¹é¢çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°æŠ—ç”Ÿç´ æŠ—è—¥æ€§ç´°èŒçš„æŒ‘æˆ°ã€‚ç ”ç©¶è€…å€‘ç³»çµ±æ€§åœ°å›é¡§äº†ç¾æœ‰æ–‡ç»ï¼Œç¸½çµäº†è˜¿è””ç¡«ç´ åœ¨é«”å¤–å’Œé«”å…§çš„æŠ—èŒæ•ˆæœï¼ŒåŒ…æ‹¬å°äººé¡çš„ç ”ç©¶ã€‚é€™äº›ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—èŒç‰¹æ€§ï¼Œé‚„æ¢è¨äº†å®ƒå¦‚ä½•å½±éŸ¿ç´°èŒçš„æ¯’æ€§å› å­åŠå…ç–«åæ‡‰ï¼Œé€™äº›éƒ½æ˜¯å°æŠ—ç´°èŒæ„ŸæŸ“çš„é‡è¦å› ç´ ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å€‘å›é¡§äº†28ç¯‡ç›¸é—œå ±å‘Šï¼Œé€™äº›å ±å‘Šæ¢è¨äº†è˜¿è””ç¡«ç´ å°ä¸åŒé¡å‹çš„ç´°èŒï¼ˆåŒ…æ‹¬é©è˜­æ°é™½æ€§å’Œé©è˜­æ°é™°æ€§ç´°èŒï¼‰çš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬é«”å¤–å¯¦é©—å’Œäººé«”ç ”ç©¶ï¼Œé‡é»åˆ†æäº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èŒçš„ç”Ÿç‰©è†œå½¢æˆã€æ¯’ç´ ç”¢ç”Ÿï¼Œä»¥åŠå®ƒå°å…ç–«ç³»çµ±çš„èª¿ç¯€ä½œç”¨ã€‚é€™äº›ç ”ç©¶ç‚ºæˆ‘å€‘äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—èŒæ©Ÿåˆ¶æä¾›äº†é‡è¦çš„æ•¸æ“šæ”¯æŒã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œçš„å½¢æˆå’Œæ¯’ç´ çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤å’Œæ¸›å°‘ç™¼ç‚é€ æˆçš„ç´°èƒåŠçµ„ç¹”æå‚·ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æŠ—ç”Ÿç´ æ›¿ä»£å“ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "explanation_zh": "åœ¨ç•¶ä»Šçš„é†«ç™‚ç’°å¢ƒä¸­ï¼ŒæŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å‡ºç¾ä½¿å¾—æ²»ç™‚æ„ŸæŸ“è®Šå¾—æ›´åŠ å›°é›£ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–å…·æœ‰æŠ—èŒç‰¹æ€§çš„åŒ–åˆç‰©è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ„ŸæŸ“æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç”Ÿç´ ç„¡æ³•å¥æ•ˆçš„æƒ…æ³ä¸‹ï¼Œé€™äº›å¤©ç„¶æ¤ç‰©æˆåˆ†å¯èƒ½æˆç‚ºæœ‰æ•ˆçš„æ›¿ä»£æ–¹æ¡ˆï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°é é˜²å’Œæ²»ç™‚ç´°èŒæ„ŸæŸ“ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨æŠ—èŒæ–¹é¢çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°æŠ—ç”Ÿç´ æŠ—è—¥æ€§ç´°èŒçš„æŒ‘æˆ°ã€‚ç ”ç©¶è€…å€‘ç³»çµ±æ€§åœ°å›é¡§äº†ç¾æœ‰æ–‡ç»ï¼Œç¸½çµäº†è˜¿è””ç¡«ç´ åœ¨é«”å¤–å’Œé«”å…§çš„æŠ—èŒæ•ˆæœï¼ŒåŒ…æ‹¬å°äººé¡çš„ç ”ç©¶ã€‚é€™äº›ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—èŒç‰¹æ€§ï¼Œé‚„æ¢è¨äº†å®ƒå¦‚ä½•å½±éŸ¿ç´°èŒçš„æ¯’æ€§å› å­åŠå…ç–«åæ‡‰ï¼Œé€™äº›éƒ½æ˜¯å°æŠ—ç´°èŒæ„ŸæŸ“çš„é‡è¦å› ç´ ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å€‘å›é¡§äº†28ç¯‡ç›¸é—œå ±å‘Šï¼Œé€™äº›å ±å‘Šæ¢è¨äº†è˜¿è””ç¡«ç´ å°ä¸åŒé¡å‹çš„ç´°èŒï¼ˆåŒ…æ‹¬é©è˜­æ°é™½æ€§å’Œé©è˜­æ°é™°æ€§ç´°èŒï¼‰çš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬é«”å¤–å¯¦é©—å’Œäººé«”ç ”ç©¶ï¼Œé‡é»åˆ†æäº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èŒçš„ç”Ÿç‰©è†œå½¢æˆã€æ¯’ç´ ç”¢ç”Ÿï¼Œä»¥åŠå®ƒå°å…ç–«ç³»çµ±çš„èª¿ç¯€ä½œç”¨ã€‚é€™äº›ç ”ç©¶ç‚ºæˆ‘å€‘äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—èŒæ©Ÿåˆ¶æä¾›äº†é‡è¦çš„æ•¸æ“šæ”¯æŒã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œçš„å½¢æˆå’Œæ¯’ç´ çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤å’Œæ¸›å°‘ç™¼ç‚é€ æˆçš„ç´°èƒåŠçµ„ç¹”æå‚·ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æŠ—ç”Ÿç´ æ›¿ä»£å“ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of microbiology & immunologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ç«Ÿç„¶éš±è—è‘—å°æŠ—ç´°èŒçš„æ½›åŠ›ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™å€‹ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½æˆç‚ºå°æŠ—æŠ—ç”Ÿç´ æŠ—è—¥æ€§ç´°èŒçš„æ–°æ­¦å™¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ åœ¨æŠ—èŒæ–¹é¢çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é¢å°é‚£äº›å·²ç¶“å°æŠ—ç”Ÿç´ ç„¡æ³•å¥æ•ˆçš„ç´°èŒã€‚ç ”ç©¶è€…å€‘ä»”ç´°å›é¡§äº†28ç¯‡ç›¸é—œçš„æ–‡ç»ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°ä¸åŒé¡å‹ç´°èŒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å®ƒå¦‚ä½•å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç³»çµ±ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œé‚„èƒ½ä¿ƒé€²å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å…·å‚™æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„æ•ˆæœã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„æ„ŸæŸ“æ²»ç™‚å……æ»¿å¸Œæœ›ï¼\n\nâœ¨ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœã€‚\n2. å®ƒèƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆã€‚\n3. è˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç³»çµ±çš„åæ‡‰ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ„ŸæŸ“ã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on sulforaphane (SFN) as an antibacterial agent. The image should feature simplified icons of broccoli or sulforaphane, simplified representations of experimental subjects (like humans, animals, or cells), and arrows or flow lines indicating the steps of the experiment. Include a section labeled 'Main Findings' that highlights protective effects and changes observed in the study. Use a flat design style with a light background and soft colors.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "èƒƒç‚ Gastritis",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40553560/"
  }
]